<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0//FR" "http://www.w3.org/TR/REC-html40/strict.dtd">
<!-- template_7 -->
<HTML>
  <HEAD>
    <META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
    <META name="organization" content="ANSM : Agence Nationale de Sécurité du Médicament et des Produit de santé">
    <META name="description" content="Résumé des Caractéristiques du Produit">
    <META name="keywords" content="LEVOFLOXACINE TEVA 500 mg, comprimé pelliculé sécable, Médicament, Spécialité pharmaceutique, RCP, Résumé des Caractéristiques du Produit, Dénomination, Forme pharmaceutique, Indications, Contre-indications, Effets secondaires">
    <TITLE>Résumé des Caractéristiques du Produit</TITLE>
    <link rel="stylesheet" href="../style/spstyl01.css" type="text/css">
  </HEAD>
  <BODY>
<p class="AmmAnnexeTitre"><a name="RcpTitre">RÉSUMÉ DES CARACTÉRISTIQUES DU PRODUIT</a></p>
<p class="DateNotif">ANSM - Mis à jour le : 25/03/2014</p>
<p class="AmmAnnexeTitre1"><a name="RcpDenomination">1. DENOMINATION DU MEDICAMENT</a></p>
<p class=AmmDenomination>LEVOFLOXACINE TEVA 500 mg, comprimé pelliculé sécable</p>
<p class="AmmAnnexeTitre1"><a name="RcpCompoQualitQuanti">2. COMPOSITION QUALITATIVE ET QUANTITATIVE</a></p>
<p class=AmmComposition>Lévofloxacine ................................................................................................................................... 500 mg</p>
<p class=AmmComposition>Sous forme de lévofloxacine hémihydratée ..................................................................................... 512,46 mg</p>
<p class=AmmComposition align=center style='text-align:center'>Pour un comprimé pelliculé sécable.</p>
<p class=AmmCorpsTexte>Pour la liste complète des excipients, <a href="#Rcp_6_1_ListeExcipients_8"><span class=MsoPageNumber><span style='font-family:Arial'>voir rubrique 6.1</span></span></a>.</p>
<p class="AmmAnnexeTitre1"><a name="RcpFormePharm">3. FORME PHARMACEUTIQUE</a></p>
<p class=AmmCorpsTexte>Comprimé pelliculé sécable.</p>
<p class=AmmCorpsTexte>Comprimé pelliculé sécable en forme de capsule couleur pêche, gravé « LX » à gauche et « 500 » à droite du sillon de sécabilité d'un côté, doté d'un sillon et lisse de l'autre côté.</p>
<p class=AmmCorpsTexte>Le comprimé peut être divisé en deux demi-doses égales.</p>
<p class="AmmAnnexeTitre1"><a name="RcpDonneesCliniques">4. DONNEES CLINIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpIndicTherap">4.1. Indications thérapeutiques</a></p>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom:.0001pt; text-align:left;page-break-after:avoid'>Chez l'adulte atteint d'une infection d'intensité légère à modérée, les comprimés de lévofloxacine sont indiqués pour le traitement des infections suivantes lorsqu'elles sont provoquées par des micro-organismes sensibles à la lévofloxacine:</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>sinusite aiguë (diagnostiquée conformément aux directives nationales et/ou locales concernant le traitement des infections des voies respiratoires),</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>exacerbation aiguë de la bronchite chronique (diagnostiquée conformément aux recommandations nationales et/ou locales concernant le traitement des infections des voies respiratoires),</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>pneumonie communautaire,</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>infections des voies urinaires compliquées (y compris pyélonéphrite),</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>prostatite bactérienne chronique,</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>traitement prophylactique post-exposition et traitement curatif de la maladie du charbon.</p>
<p class=AmmCorpsTexte>Il convient de tenir compte des recommandations officielles concernant l'utilisation appropriée des antibactériens.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPosoAdmin">4.2. Posologie et mode d'administration</a></p>
<p class=AmmCorpsTexte><a name="Rcp_4_2_PosoAdmin_1"></a>Ce médicament est administré en une ou deux prises quotidiennes.</p>
<p class=AmmCorpsTexte>La posologie est fonction du type et de la gravité de l'infection et de la sensibilité du germe en cause.</p>
<p class=AmmCorpsTexte><b><u>Durée du traitement</u>:</b></p>
<p class=AmmCorpsTexte>La durée du traitement dépend de l'évolution de la pathologie (voir tableau ci-dessous).</p>
<p class=AmmCorpsTexte>Comme tout traitement antibiotique, l'administration des comprimés de lévofloxacine doit être poursuivie pendant au moins 48 à 72 heures après disparition de la fièvre ou après éradication bactérienne documentée.</p>
<p class=AmmCorpsTexte><b><u>Mode d'administration</u>:</b></p>
<p class=AmmCorpsTexte>Les comprimés de lévofloxacine doivent être avalés entiers avec une quantité suffisante de liquide. Les comprimés peuvent être pris pendant ou entre les repas.</p>
<p class=AmmCorpsTexte>Les comprimés de lévofloxacine doivent être pris au moins deux heures avant les sels de fer, les anti-acides et le sucralfate car leur absorption risquerait d'être diminuée (<a href="#Rcp_4_5_Interactions_4"><span class=MsoPageNumber><span style='font-family:Arial'>voir rubrique 4.5</span></span></a>).</p>
<p class=AmmCorpsTexte><b><u>Posologie</u>:</b></p>
<p class=AmmCorpsTexte><b>Patients à fonction rénale normale</b></p>
<p class=AmmCorpsTexte><i>(clairance de la créatinine &gt; 50 ml/min)</i></p>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='margin-left:3.5pt;border-collapse:collapse;border:none'>
<thead>
<tr>
<td width=340 style='width:254.75pt;border:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>Indication</p>
</td>
<td width=204 style='width:152.85pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>Posologie quotidienne (selon la gravité)</p>
</td>
<td width=136 style='width:101.9pt;border:solid windowtext 1.0pt;border-left:
none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1 align=center style='margin:0cm;margin-bottom:.0001pt; text-align:center'>Durée du traitement</p>
</td>
</tr>
<tr>
<td width=340 valign=top style='width:254.75pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Sinusite aiguë</p>
</td>
<td width=204 valign=top style='width:152.85pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>500 mg une fois par jour</p>
</td>
<td width=136 valign=top style='width:101.9pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>10-14 jours</p>
</td>
</tr>
<tr>
<td width=340 valign=top style='width:254.75pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Exacerbation aiguë de la bronchitechronique</p>
</td>
<td width=204 valign=top style='width:152.85pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>250-500 mg une fois parjour</p>
</td>
<td width=136 valign=top style='width:101.9pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>7-10 jours</p>
</td>
</tr>
<tr>
<td width=340 valign=top style='width:254.75pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Pneumonie communautaire</p>
</td>
<td width=204 valign=top style='width:152.85pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>500 mg une ou deux fois par jour</p>
</td>
<td width=136 valign=top style='width:101.9pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>7-14 jours</p>
</td>
</tr>
<tr>
<td width=340 valign=top style='width:254.75pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Infections des voiesurinaires compliquées (y compris pyélonéphrite)</p>
</td>
<td width=204 valign=top style='width:152.85pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>250 mg une fois par jour</p>
</td>
<td width=136 valign=top style='width:101.9pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>7 - 10 jours</p>
</td>
</tr>
<tr>
<td width=340 valign=top style='width:254.75pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Prostatite bactérienne chronique</p>
</td>
<td width=204 valign=top style='width:152.85pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>500 mg une fois par jour</p>
</td>
<td width=136 valign=top style='width:101.9pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>28 jours</p>
</td>
</tr>
<tr>
<td width=340 valign=top style='width:254.75pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Traitement prophylactique et curatif dela maladie du charbon chez des patients symptomatiques pouvant prendre directement un traitement oral, ou après un traitement parentéral</p>
</td>
<td width=204 valign=top style='width:152.85pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>500 mg une fois par jour</p>
</td>
<td width=136 valign=top style='width:101.9pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>8 semaines lorsque l'exposition au charbon est avérée</p>
</td>
</tr>
</thead>
</table>
<p class=AmmCorpsTexte><b><u>Populations particulières</u></b></p>
<p class=AmmCorpsTexte><b>Insuffisant rénal</b></p>
<p class=AmmCorpsTexte><i>(clairance de la créatinine &#8804;50 ml/min)</i></p>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='margin-left:3.5pt;border-collapse:collapse;border:none'>
<thead>
<tr>
<td width=169 style='width:126.5pt;border:solid windowtext 1.0pt;padding:
0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1> </p>
</td>
<td width=169 style='width:126.5pt;border:solid windowtext 1.0pt;border-left:
none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left'>Posologie</p>
</td>
<td width=169 style='width:126.5pt;border:solid windowtext 1.0pt;border-left:
none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left'> </p>
</td>
<td width=169 style='width:126.5pt;border:solid windowtext 1.0pt;border-left:
none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left'> </p>
</td>
</tr>
<tr>
<td width=169 style='width:126.5pt;border:solid windowtext 1.0pt;border-top:
none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1> </p>
</td>
<td width=169 style='width:126.5pt;border-top:none;border-left:none;
border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left'>250 mg/24 h</p>
</td>
<td width=169 style='width:126.5pt;border-top:none;border-left:none;
border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left'>500 mg/24 h</p>
</td>
<td width=169 style='width:126.5pt;border-top:none;border-left:none;
border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmTableauTitre1 align=left style='margin:0cm;margin-bottom:.0001pt; text-align:left'>500 mg/12 h</p>
</td>
</tr>
<tr>
<td width=169 valign=top style='width:126.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'><b>Clairance de la créatinine</b></p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Dose initiale<br> 250 mg</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Dose initiale<br> 500 mg</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Dose initiale<br> 500 mg</p>
</td>
</tr>
<tr>
<td width=169 valign=top style='width:126.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>50 - 20 ml/min</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>puis: 125 mg/24 h</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>puis: 250 mg/24 h</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>puis: 250 mg/12 h</p>
</td>
</tr>
<tr>
<td width=169 valign=top style='width:126.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>19 - 10 ml/min</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>puis: 125 mg/48 h puis:</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>puis: 125 mg/24 h</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>puis: 125 mg/12 h</p>
</td>
</tr>
<tr>
<td width=169 valign=top style='width:126.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>&lt;10 ml/min (y comprishémodialyse et DPCA)<sup>1</sup></p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>puis: 125 mg/48 h</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>puis: 125 mg/24 h</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>puis: 125 mg/24 h</p>
</td>
</tr>
</thead>
</table>
<p class=AmmCorpsTexte><sup>1</sup>Aucune dose supplémentaire n'est nécessaire après hémodialyse ou dialyse péritonéale continue ambulatoire (DPCA).</p>
<p class=AmmCorpsTexte><b>Insuffisant hépatique</b></p>
<p class=AmmCorpsTexte>Aucune adaptation posologique n'est nécessaire car la lévofloxacine est peu métabolisée par le foie et est principalement excrétée par les reins.</p>
<p class=AmmCorpsTexte><b>Personne âgée</b></p>
<p class=AmmCorpsTexte>Aucune adaptation posologique n'est nécessaire chez le sujet âgé en dehors de l'adaptation indiquée par la fonction rénale (<a href="#Rcp_4_4_MisesEnGarde_3"><span class=MsoPageNumber><span style='font-family:Arial'>voir rubrique 4.4 Allongement de l'intervalle QT</span></span></a>).</p>
<p class=AmmCorpsTexte><b>Enfant</b></p>
<p class=AmmCorpsTexte>L'utilisation de la lévofloxacine chez l'enfant et l'adolescent en phase de croissance est contre-indiquée (<a href="#Rcp_4_3_ContreIndic_2"><span class=MsoPageNumber><span style='font-family: Arial'>voir rubrique 4.3</span></span></a>).</p>
<p class="AmmAnnexeTitre2"><a name="RcpContreIndic">4.3. Contre-indications</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278910"></a><a name="Rcp_4_3_ContreIndic_2"></a>Les comprimés de lévofloxacine ne doivent pas être utilisés<span style='letter-spacing:-.15pt'>:</span></p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>en cas d<span style='letter-spacing:-.1pt'></span>hypersensi<span style='letter-spacing:-.1pt'>b</span><span style='letter-spacing:.1pt'>ilit</span>é<span style='letter-spacing:-.2pt'> </span>à<span style='letter-spacing:-.1pt'> </span>la<span style='letter-spacing:-.1pt'> </span>lé<span style='letter-spacing:.5pt'>v</span>ofloxacine, à dautres quinolones ou à lun des excipient<span style='letter-spacing:-.25pt'>s</span>,</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>chez les patients<span style='letter-spacing:.05pt'> </span>épileptiques</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>chez les<span style='letter-spacing:.65pt'> </span>patients présentant <span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing:.55pt'> </span>antécédents<span style='letter-spacing: .65pt'> </span><span style='letter-spacing:-.1pt'>d</span>e tendinopathies <span style='letter-spacing:.15pt'>li</span><span style='letter-spacing:-.1pt'>ée</span>s à la<span style='letter-spacing:-.1pt'>d</span>ministration <span style='letter-spacing:-.1pt'>de </span>fluoroquinolone,</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>chez lenfant et ladolescent<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>e</span>n <span style='letter-spacing:-.1pt'>phas</span>e<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.05pt'> </span>croissa<span style='letter-spacing:-.1pt'>n</span>ce</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>pendant la grossesse</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>chez la femme qui allaite.</p>
<p class="AmmAnnexeTitre2"><a name="RcpMisesEnGarde">4.4. Mises en garde spéciales et précautions d'emploi</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278911"></a><a name="Rcp_4_4_MisesEnGarde_3"></a><span style='letter-spacing:-.1pt'>Dan</span>s<span style='letter-spacing:2.5pt'> </span><span style='letter-spacing:-.05pt'>le</span>s <span style='letter-spacing:-.05pt'>ca</span>s <span style='letter-spacing: -.05pt'>le</span>s <span style='letter-spacing:-.05pt'>plu</span>s <span style='letter-spacing:-.05pt'>gra</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.15pt'>e</span>s<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:2.5pt'> </span>pneumonie à <span style='letter-spacing:-.05pt'>pneumocoque</span>, <span style='letter-spacing:.05pt'>l</span>a <span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine<span style='letter-spacing:2.6pt'> </span><span style='letter-spacing:-.1pt'>nes</span>t<span style='letter-spacing: 2.5pt'> </span>pas <span style='letter-spacing:-.05pt'>nécessairemen</span>t<span style='letter-spacing:-.05pt'> l</span>e<span style='letter-spacing:-.05pt'> traitemen</span>t<span style='letter-spacing:-.05pt'> optimal.</span></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Les infections nosocomiales dues à <i>P. aeruginosa</i> peuvent nécessiter une association de traitement.</span></p>
<p class=AmmCorpsTexte>Le <i>S. aureus</i> méthic<span style='letter-spacing: -.2pt'>i</span><span style='letter-spacing:.05pt'>llin</span><span style='letter-spacing:-.35pt'>e</span><span style='letter-spacing:-.1pt'>-</span><span style='letter-spacing:.4pt'>r</span><span style='letter-spacing:-.35pt'>é</span>sistant possède très probablement une <span style='letter-spacing:.15pt'>r</span><span style='letter-spacing:-.35pt'>é</span>sistance croisée aux fluoroquinolones, dont<span style='letter-spacing:-.05pt'> </span>la<span style='letter-spacing: -.05pt'> </span>lévofloxacine.<span style='letter-spacing:-.05pt'> </span>Par<span style='letter-spacing:-.05pt'> </span>conséquent,<span style='letter-spacing: -.05pt'> </span>la<span style='letter-spacing:-.05pt'> </span>lévofloxacine<span style='letter-spacing:-.05pt'> </span>nest<span style='letter-spacing:-.05pt'> </span>pas<span style='letter-spacing:-.05pt'> </span>recommandée<span style='letter-spacing:-.05pt'> </span>dans<span style='letter-spacing:-.05pt'> </span>le<span style='letter-spacing:-.05pt'> </span>traitement<span style='letter-spacing: .25pt'> </span><span style='letter-spacing:-.1pt'>des </span>infections<span style='letter-spacing:-.05pt'> </span>à<span style='letter-spacing:-.05pt'> </span>SAMR<span style='letter-spacing:-.05pt'> </span>connu<span style='letter-spacing:-.05pt'> </span>ou<span style='letter-spacing:-.05pt'> </span>suspecté<span style='letter-spacing:-.05pt'> </span>à<span style='letter-spacing:-.05pt'> </span>moins<span style='letter-spacing:-.05pt'> </span>que<span style='letter-spacing:-.05pt'> </span>les<span style='letter-spacing:-.05pt'> </span>résultats<span style='letter-spacing: -.05pt'> </span>des<span style='letter-spacing:-.05pt'> </span>tests<span style='letter-spacing:-.05pt'> </span>de<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>laboratoir</span>e<span style='letter-spacing: -.05pt'> naient </span>confirmé<span style='letter-spacing:-.05pt'> </span>la<span style='letter-spacing:-.05pt'> </span>sensibilité<span style='letter-spacing: -.05pt'> </span>du<span style='letter-spacing:-.05pt'> </span>germe<span style='letter-spacing:-.05pt'> </span>à<span style='letter-spacing:-.05pt'> </span>la<span style='letter-spacing:-.05pt'> </span>lévofloxacine.</p>
<p class=AmmCorpsTexte><b><span style='letter-spacing:.3pt'>T</span><span style='letter-spacing:-.35pt'>e</span><span style='letter-spacing:-.05pt'>ndinit</span>e<span style='letter-spacing:-.05pt'> e</span>t<span style='letter-spacing:-.05pt'> ruptur</span>e<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> tendon</span></b></p>
<p class=AmmCorpsTexte>Une tendinite peut survenir, rarement. Elle touche le plus souvent le tendon dAchille et peut provoquer une rupture de tendon. Les tendinites et les ruptures du tendon, parfois bilatérales, peuvent survenir dans les 48 heures après le début du traitement par la lévofloxacine et ont été rapportées jusquà plusieurs mois après larrêt du traitement. Le risque de tendinite et de rupture tendineuse est accru chez les patients âgés de plus de 65 ans et chez les patients sous corticothérapie y compris les corticostéroïdes en inhalation. Il est nécessaire dadapter la dose quotidienne chez le sujet âgé en fonction de la clairance de la créatinine (voir rubrique 4.2). Une étroite surveillance est donc de rigueur en cas de prescription de lévofloxacine chez ces patients. Il doit être conseillé à tous les patients de consulter leur médecin s'ils présentent des symptômes de tendinite. En cas de suspicion de tendinite, il faut immédiatement arrêter l'administration de lévofloxacine et instaurer un traitement approprié du tendon affecté (par exemple immobilisation) (voir rubriques 4.3 et 4.8).</p>
<p class=AmmCorpsTexte><b><span style='color:black;letter-spacing:-.05pt'>Pathologie</span><span style='color:black'>s<span style='letter-spacing:-.05pt'> associée</span>s<span style='letter-spacing:-.05pt'> </span>à<span style='letter-spacing:.05pt'> </span><i><span style='letter-spacing:-.05pt'>Clostridiu</span>m<span style='letter-spacing: -.05pt'> difficile</span></i></span></b></p>
<p class=AmmCorpsTexte style='margin-left:7.1pt;page-break-after:avoid'>Une diarrhée, surtout si elle est sévère, persistante et/ou sanglante, survenant pendant ou après un traitement par LEVOFLOXACINE TEVA 500 mg, comprimé pelliculé sécable (y compris plusieurs semaines après le traitement) peut traduire une entérite due à <i>Clostridium difficile</i>. La gravité des maladies associées à <i>Clostridium difficile</i> (MACD) peut être modérée voire jusquà menacer le pronostic vital, la forme la plus grave étant la colite pseudomembraneuse (voir rubrique 4.8). Ce diagnostic doit être envisagé chez les patients présentant des diarrhées sévères durant ou après le traitement par la lévofloxacine. En cas de suspicion ou de confirmation de MACD, il faut immédiatement arrêter l'administration de LEVOFLOXACINE TEVA 500 mg, comprimé pelliculé sécable et instaurer sans tarder un traitement approprié. L'usage de médicaments inhibiteurs du péristaltisme intestinal est contre-indiqué dans cette situation clinique.</p>
<p class=AmmCorpsTexteGras>P<span style='letter-spacing:-.1pt'>a</span><span style='letter-spacing:-.05pt'>tient</span>s<span style='letter-spacing:-.05pt'> prédisposé</span>s<span style='letter-spacing:-.05pt'> au</span>x<span style='letter-spacing:-.05pt'> convulsions</span></p>
<p class=AmmCorpsTexte>Les quinolones peuvent diminuer le seuil épileptogène et déclencher des convulsions. Les comprimés de lévofloxacine sont contre-indiqués en cas d'antécédents d'épilepsie (voir rubrique 4.3) et, comme pour les autres quinolones, il faut utiliser la lévofloxacine avec une extrême prudence chez les patients prédisposés aux crises d'épilepsie, ou recevant un traitement concomitant par des médicaments qui abaissent le seuil épileptogène, tels que la théophylline (voir rubrique 4.5). En cas de crise comitiale (voir rubrique 4.8), le traitement par la lévofloxacine doit être interrompu.</p>
<p class=AmmCorpsTexteGras>Patients atteints dun déficit<span style='letter-spacing:.1pt'> </span>en<span style='letter-spacing:-.1pt'> </span>glucos<span style='letter-spacing:-.1pt'>e</span>-<span style='letter-spacing:-.1pt'>6</span>-phosphate déshydrogénase</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.15pt'>Le</span>s <span style='letter-spacing:-.05pt'>patient</span>s <span style='letter-spacing:-.05pt'>présentan</span>t<span style='letter-spacing:1.35pt'> </span><span style='letter-spacing:-.05pt'>de</span>s<span style='letter-spacing:1.35pt'> </span><span style='letter-spacing:-.05pt'>défaut</span>s<span style='letter-spacing:1.35pt'> </span><span style='letter-spacing:-.05pt'>latent</span>s <span style='letter-spacing:-.1pt'>o</span>u <span style='letter-spacing:.05pt'>actif</span>s <span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.1pt'> </span>lactivité<span style='letter-spacing:1.4pt'> </span><span style='letter-spacing:-.1pt'>d</span>e <span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:1.45pt'> </span><span style='letter-spacing:-.35pt'>g</span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.1pt'>ucose</span>-<span style='letter-spacing:-.1pt'>6</span>-phosphate <span style='letter-spacing: -.05pt'>déshydrogénas</span>e<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.1pt'>peu</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>en</span>t<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>présente</span>r<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing: 1.65pt'> </span><span style='letter-spacing:-.05pt'>réaction</span>s<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>hémolytique</span>s<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>lor</span>s<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.1pt'>du</span>n<span style='letter-spacing:1.7pt'> </span>traitement<span style='letter-spacing: 1.75pt'> </span><span style='letter-spacing:-.05pt'>pa</span>r<span style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.05pt'>le</span>s<span style='letter-spacing:1.7pt'> </span>agents <span style='letter-spacing:-.05pt'>antibactérien</span>s<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:2.05pt'> </span><span style='letter-spacing:-.05pt'>class</span>e<span style='letter-spacing:2.2pt'> </span><span style='letter-spacing:-.05pt'>de</span>s<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.05pt'>quinolone</span>s<span style='letter-spacing:-.1pt'> </span>;<span style='letter-spacing:2.15pt'> </span>cest<span style='letter-spacing:2.0pt'> </span>pourquoi<span style='letter-spacing:2.0pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing: 2.05pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine<span style='letter-spacing:2.0pt'> </span>doit<span style='letter-spacing:2.05pt'> </span>être<span style='letter-spacing:2.0pt'> </span><span style='letter-spacing:-.05pt'>utilisé</span>e<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>ec </span>précaution chez c<span style='letter-spacing:-.1pt'>e</span>s<span style='letter-spacing: -.1pt'> </span><span style='letter-spacing:-.05pt'>patients.</span></p>
<p class=AmmCorpsTexteGras>Patients insuffisants rénaux</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>D</span>u<span style='letter-spacing:2.4pt'> </span><span style='letter-spacing:.05pt'>fai</span>t<span style='letter-spacing:2.55pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:2.4pt'> </span>l'excrétion<span style='letter-spacing: 2.45pt'> </span><span style='letter-spacing:-.05pt'>essentiellemen</span>t<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.05pt'>rénal</span>e<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:2.4pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:2.55pt'> </span><span style='letter-spacing:-.2pt'>lé</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>ofloxacine</span>,<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.1pt'>un</span>e<span style='letter-spacing:2.4pt'> </span><span style='letter-spacing:-.05pt'>adaptatio</span>n<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.05pt'>posologiqu</span>e<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:.1pt'>est </span><span style='letter-spacing:-.05pt'>nécessair</span>e<span style='letter-spacing: -.05pt'> che</span>z<span style='letter-spacing:-.05pt'> le</span>s<span style='letter-spacing:-.05pt'> insuffisant</span>s<span style='letter-spacing: -.05pt'> rénau</span>x<span style='letter-spacing:.35pt'> </span><span style='letter-spacing:-.05pt'>(voi</span>r<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>rubriqu</span>e<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.1pt'>4.2).</span></p>
<p class=AmmCorpsTexteGras>Réactions d'hypersensibilité</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>L</span>a<span style='letter-spacing:2.15pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine<span style='letter-spacing:2.25pt'> </span><span style='letter-spacing:-.05pt'>peu</span>t<span style='letter-spacing: 2.2pt'> </span><span style='letter-spacing:-.05pt'>pr</span><span style='letter-spacing:-.3pt'>o</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.1pt'>o</span><span style='letter-spacing:-.05pt'>que</span>r<span style='letter-spacing:2.2pt'> </span><span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing:2.1pt'> </span><span style='letter-spacing:-.05pt'>réaction</span>s<span style='letter-spacing:2.2pt'> </span>dhypersensibilité<span style='letter-spacing: 2.25pt'> </span><span style='letter-spacing:-.05pt'>graves</span>,<span style='letter-spacing:2.2pt'> </span>potentiellem<span style='letter-spacing: -.1pt'>en</span>t<span style='letter-spacing:1.9pt'> </span>mortelles <span style='letter-spacing:-.05pt'>(pa</span>r<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>exempl</span>e<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>dèm</span>e<span style='letter-spacing: 1.75pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.45pt'> </span>Quincke<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.1pt'>o</span>u<span style='letter-spacing: 1.7pt'> </span><span style='letter-spacing:-.05pt'>cho</span>c<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>anaphylactique)</span>,<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>parfoi</span>s<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.15pt'>dè</span>s<span style='letter-spacing:1.65pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:1.8pt'> </span>première<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.05pt'>administration </span><span style='letter-spacing:-.25pt'>(</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.35pt'>o</span><span style='letter-spacing:.15pt'>i</span>r<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>rubriqu</span>e<span style='letter-spacing:1.7pt'> </span>4.8).<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.15pt'>Le</span>s<span style='letter-spacing:1.9pt'> </span><span style='letter-spacing:-.05pt'>patient</span>s<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.1pt'>doi</span><span style='letter-spacing: .5pt'>v</span><span style='letter-spacing:-.05pt'>en</span>t<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>interrompr</span>e<span style='letter-spacing:1.75pt'> </span>immédiatement<span style='letter-spacing: 1.5pt'> </span><span style='letter-spacing:.05pt'>l</span>e<span style='letter-spacing:1.8pt'> </span>traitement<span style='letter-spacing: 1.75pt'> </span>et<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>co</span><span style='letter-spacing:-.1pt'>n</span><span style='letter-spacing:.15pt'>tacte</span>r<span style='letter-spacing:.35pt'> </span><span style='letter-spacing:.15pt'>leur </span><span style='letter-spacing:-.05pt'>médeci</span>n<span style='letter-spacing:-.05pt'> o</span>u<span style='letter-spacing:-.05pt'> u</span>n<span style='letter-spacing:-.05pt'> servic</span>e<span style='letter-spacing:-.05pt'> durgenc</span>e<span style='letter-spacing:-.05pt'> afi</span>n<span style='letter-spacing:-.05pt'> qu</span>e<span style='letter-spacing:-.05pt'> le</span>s<span style='letter-spacing:-.05pt'> mesure</span>s<span style='letter-spacing:-.05pt'> durgenc</span>e<span style='letter-spacing: -.05pt'> appropriée</span>s<span style='letter-spacing:-.05pt'> soien</span>t<span style='letter-spacing:-.05pt'> mise</span>s<span style='letter-spacing:-.05pt'> e</span>n<span style='letter-spacing:-.05pt'> place.</span></p>
<p class=AmmCorpsTexteGras>Troubles de la glycémie</p>
<p class=AmmCorpsTexte>Comme avec toutes les quinolones, des modifications du glucose sanguin, incluant à la fois des cas d'hypoglycémie et dhyperglycémie, ont été <span style='letter-spacing:-.05pt'>rapportées</span>,<span style='letter-spacing:1.0pt'> </span>généraleme<span style='letter-spacing: -.1pt'>n</span>t<span style='letter-spacing:.95pt'> </span><span style='letter-spacing:-.05pt'>che</span>z<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing:.95pt'> </span><span style='letter-spacing:-.05pt'>patient</span>s<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.05pt'>diabétique</span>s<span style='letter-spacing:1.05pt'> </span>prenant<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.1pt'>u</span>n<span style='letter-spacing: 1.0pt'> </span>traitement <span style='letter-spacing:-.05pt'>concomitan</span>t <span style='letter-spacing:-.05pt'>pa</span>r <span style='letter-spacing: -.05pt'>u</span>n <span style='letter-spacing:-.05pt'>agen</span>t <span style='letter-spacing:-.05pt'>hypoglycémian</span>t <span style='letter-spacing: -.05pt'>ora</span>l <span style='letter-spacing:-.05pt'>(pa</span>r <span style='letter-spacing:-.05pt'>exempl</span>e <span style='letter-spacing:-.05pt'>glibenclamide</span>) <span style='letter-spacing:-.05pt'>o</span>u <span style='letter-spacing:-.05pt'>pa</span>r <span style='letter-spacing:-.05pt'>linsuline</span>. <span style='letter-spacing: -.05pt'>Che</span>z <span style='letter-spacing:-.05pt'>ces patient</span>s<span style='letter-spacing:-.05pt'> diabétiques</span>,<span style='letter-spacing: -.05pt'> un</span>e<span style='letter-spacing:-.05pt'> sur</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>eillanc</span>e<span style='letter-spacing:-.05pt'> étroit</span>e<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> l</span>a<span style='letter-spacing: -.05pt'> glycém</span><span style='letter-spacing:.15pt'>i</span>e<span style='letter-spacing:-.05pt'> es</span>t<span style='letter-spacing:-.05pt'> recommandée</span>.<span style='letter-spacing:-.05pt'> (Voi</span>r<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>rubriqu</span>e<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>4.8).</span></p>
<p class=AmmCorpsTexteGras>Prévention de la photosensibilisation</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Un</span>e<span style='letter-spacing:.75pt'> </span><span style='letter-spacing:-.05pt'>photosensibilisatio</span>n<span style='letter-spacing:.8pt'> </span>a<span style='letter-spacing:.75pt'> </span><span style='letter-spacing:-.05pt'>ét</span>é<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>rapporté</span>e<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing: .25pt'>v</span><span style='letter-spacing:-.05pt'>e</span>c<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>(voi</span>r<span style='letter-spacing: .8pt'> </span><span style='letter-spacing:-.05pt'>rubriqu</span>e<span style='letter-spacing:.8pt'> </span>4.8).<span style='letter-spacing:.6pt'> </span><span style='letter-spacing:.1pt'>I</span>l<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.1pt'>es</span>t<span style='letter-spacing:.75pt'> </span><span style='letter-spacing:-.05pt'>recommandé </span><span style='letter-spacing: -.15pt'>dé</span><span style='letter-spacing:.5pt'>v</span>iter<span style='letter-spacing:.05pt'> </span>lexposition<span style='letter-spacing: .05pt'> </span>au<span style='letter-spacing:.05pt'> </span>soleil<span style='letter-spacing:.05pt'> </span>et<span style='letter-spacing:.05pt'> </span>aux<span style='letter-spacing:.05pt'> </span>rayonnements<span style='letter-spacing: -.1pt'> </span>UV<span style='letter-spacing:.1pt'> </span>(lampe<span style='letter-spacing:.1pt'> </span>à<span style='letter-spacing:.1pt'> </span>bronze<span style='letter-spacing:.05pt'>r</span>,<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:-.25pt'>s</span><span style='letter-spacing:-.05pt'>olariu</span><span style='letter-spacing:.25pt'>m</span>)<span style='letter-spacing:.1pt'> </span>pendant la durée <span style='letter-spacing:-.1pt'>d</span>u traitement et <span style='letter-spacing:-.1pt'>dan</span>s <span style='letter-spacing:-.05pt'>le</span>s <span style='letter-spacing:-.1pt'>4</span>8 <span style='letter-spacing:-.05pt'>heure</span>s s<span style='letter-spacing:-.05pt'>ui</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.1pt'>an</span>t <span style='letter-spacing:-.05pt'>larrê</span>t<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:-.05pt'>celu</span><span style='letter-spacing:.15pt'>i</span>-<span style='letter-spacing:-.25pt'>c</span>i <span style='letter-spacing:-.1pt'>e</span>n<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:-.05pt'>raiso</span>n <span style='letter-spacing:-.1pt'>d</span>u <span style='letter-spacing:-.05pt'>risqu</span>e<span style='letter-spacing: .5pt'> </span><span style='letter-spacing:.05pt'>de </span><span style='letter-spacing:-.05pt'>photosensibilisation</span>.</p>
<p class=AmmCorpsTexteGras>Patients traités par antagonistes de la vitamine K</p>
<p class=AmmCorpsTexte>Du fait de l'allongement possible des paramètres de la coagulation (PT/INR)<span style='letter-spacing:.55pt'> </span>et/ou<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:-.05pt'>cas </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:-.05pt'>saign</span><span style='letter-spacing:-.1pt'>e</span><span style='letter-spacing:.05pt'>men</span>t<span style='letter-spacing:.65pt'> </span><span style='letter-spacing:-.05pt'>che</span>z<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.05pt'>le</span>s<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.05pt'>patient</span>s<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.05pt'>traité</span>s<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.05pt'>pa</span>r<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.65pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.3pt'>o</span><span style='letter-spacing:-.05pt'>floxacin</span>e<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.1pt'>e</span>n<span style='letter-spacing:.5pt'> </span>association<span style='letter-spacing: .55pt'> </span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.15pt'>e</span>c<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:-.1pt'>u</span>n<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:-.05pt'>antagonist</span>e<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:.15pt'>la </span>vitamine<span style='letter-spacing:.45pt'> </span>K<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:-.05pt'>(pa</span>r <span style='letter-spacing:.4pt'></span><span style='letter-spacing:-.05pt'>exempl</span>e<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:-.05pt'>warfarine)</span>,<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:-.05pt'>le</span>s <span style='letter-spacing:-.05pt'>test</span>s <span style='letter-spacing: -.1pt'>d</span>e <span style='letter-spacing:.05pt'>l</span>a coagulation doivent<span style='letter-spacing:.45pt'> </span>être <span style='letter-spacing: -.2pt'>sur</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>eillé</span>s <span style='letter-spacing:-.1pt'>e</span>n<span style='letter-spacing:.4pt'> </span><span style='letter-spacing:.15pt'>cas </span><span style='letter-spacing:-.05pt'>dadministratio</span>n<span style='letter-spacing: -.05pt'> concomitant</span>e<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> ce</span>s<span style='letter-spacing:-.05pt'> médicament</span>s<span style='letter-spacing:-.05pt'> (voi</span>r<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>rubriqu</span>e<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>4.5</span><span style='letter-spacing:-.25pt'>)</span>.</p>
<p class=AmmCorpsTexteGras>Réactions psychotiques</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.15pt'>De</span>s<span style='letter-spacing:.7pt'> </span><span style='letter-spacing:-.05pt'>réaction</span>s<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>psychotique</span>s<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>on</span>t<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>ét</span>é<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>rapportée</span>s<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>che</span>z<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>le</span>s<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>patient</span>s<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>rece</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>an</span>t<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing:.7pt'> </span><span style='letter-spacing:-.05pt'>quinolones</span>,<span style='letter-spacing:.8pt'> </span>y<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.05pt'>compris </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:1.1pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine.<span style='letter-spacing: 1.05pt'> </span><span style='letter-spacing:-.1pt'>D</span><span style='letter-spacing:-.15pt'>an</span>s<span style='letter-spacing:.95pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:.1pt'>trè</span>s<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:.1pt'>rare</span>s<span style='letter-spacing:1.15pt'> </span><span style='letter-spacing:.1pt'>cas</span>,<span style='letter-spacing:.25pt'> </span><span style='letter-spacing:.1pt'>ce</span>s<span style='letter-spacing:1.2pt'> </span><span style='letter-spacing:-.05pt'>réaction</span>s<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.05pt'>on</span>t<span style='letter-spacing: 1.05pt'> </span>mené<span style='letter-spacing:1.05pt'> </span>à<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.05pt'>de</span>s<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.05pt'>pensée</span>s<span style='letter-spacing:1.3pt'> </span><span style='letter-spacing:-.05pt'>suicidaire</span>s<span style='letter-spacing:1.05pt'> </span>et<span style='letter-spacing:1.05pt'> </span>à<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:.05pt'>un </span><span style='letter-spacing:-.05pt'>comportemen</span>t<span style='letter-spacing: -.05pt'> d</span>e<span style='letter-spacing:-.05pt'> mis</span>e<span style='letter-spacing:-.05pt'> e</span>n<span style='letter-spacing:-.05pt'> danger</span>,<span style='letter-spacing:.15pt'> </span>parfois<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:-.05pt'>dè</span>s<span style='letter-spacing:-.05pt'> l</span>a<span style='letter-spacing:-.05pt'> premièr</span>e<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>dos</span>e<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> lé</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>ofloxacin</span>e<span style='letter-spacing: -.1pt'> </span><span style='letter-spacing:-.05pt'>(</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.35pt'>o</span><span style='letter-spacing:.15pt'>i</span>r<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>rubriqu</span>e<span style='letter-spacing:.05pt'> </span>4.8).<span style='letter-spacing:.05pt'> </span>Si <span style='letter-spacing:.05pt'>l</span>e <span style='letter-spacing:1.0pt'></span>patient<span style='letter-spacing:.95pt'> </span><span style='letter-spacing:-.2pt'>dé</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.35pt'>e</span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.1pt'>opp</span>e<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.05pt'>c</span>e type <span style='letter-spacing:-.1pt'>d</span>e réactions, <span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span>vofloxacine<span style='letter-spacing:.95pt'> </span>doit être <span style='letter-spacing: -.05pt'>arrêté</span>e<span style='letter-spacing:.9pt'> </span>et <span style='letter-spacing:-.05pt'>de</span>s mesures <span style='letter-spacing: -.05pt'>appropriée</span>s<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.1pt'>doi</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>en</span>t<span style='letter-spacing:.8pt'> </span>être<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>instaurées</span>.<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:.1pt'>I</span>l<span style='letter-spacing:1.0pt'> </span>convient<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>dêtr</span>e<span style='letter-spacing: .8pt'> </span><span style='letter-spacing:-.05pt'>pruden</span>t<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:.05pt'>e</span>n<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.05pt'>ca</span>s<span style='letter-spacing:.8pt'> </span>dutilisation<span style='letter-spacing: .85pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.75pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.35pt'>é</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>ofloxacine che</span>z <span style='letter-spacing: -.05pt'>de</span>s <span style='letter-spacing:-.05pt'>patient</span>s<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.05pt'>psychotique</span>s<span style='letter-spacing:-.05pt'> o</span>u<span style='letter-spacing:-.05pt'> ayan</span>t<span style='letter-spacing:.05pt'> </span><span style='letter-spacing: -.1pt'>de</span>s<span style='letter-spacing:-.2pt'> </span>antécéden<span style='letter-spacing:.1pt'>t</span>s<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.05pt'>d</span>e <span style='letter-spacing:-.05pt'>maladi</span>e <span style='letter-spacing:-.05pt'>psychiatrique.</span></p>
<p class=AmmCorpsTexteGras>Troubles cardiaques</p>
<p class=AmmCorpsTexte>La prudence est recommandée lors dun traitement par fluoroquinolones y compris la lévofloxacine chez des patients présentant des facteurs de risques connus pour allonger lintervalle QT tels que :</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>un syndrome du QT long congénital,</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>un traitement concomitant avec des médicaments connus pour allonger lintervalle QT (par exemple, les anti-arythmiques de classe IA et III, les antidépresseurs tricycliques, les macrolides, les antipsychotiques),</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>un déséquilibre électrolytique non corrigé (par exemple, lhypokaliémie, lhypomagnésémie),</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>les patients âgés,</p>
<p class=AmmListePuces1 style='text-align:justify'><span style='font-family: Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>des manifestations cardiaques (telles quune insuffisance cardiaque, un infarctus du myocarde ou une bradycardie).</p>
<p class=ammcorpstexte0 style='margin-left:7.1pt;text-align:justify'><span style='font-size:10.0pt'>(Voir rubrique 4.2 chez le patient âgé, rubriques 4.5, 4.8 et 4.9). </span></p>
<p class=AmmCorpsTexteGras style='margin-top:6.0pt'>Neuropathie périphérique</p>
<p class=AmmCorpsTexte>Des cas de neuropathies périphériques sensorielles ou sensitivomotrices ont<span style='letter-spacing:.05pt'> </span>été <span style='letter-spacing:-.05pt'>rapporté</span>s<span style='letter-spacing:1.8pt'> </span><span style='letter-spacing:-.05pt'>che</span>z <span style='letter-spacing: -.05pt'>de</span>s <span style='letter-spacing:1.85pt'></span><span style='letter-spacing:-.05pt'>patient</span>s <span style='letter-spacing:1.85pt'></span><span style='letter-spacing:-.05pt'>rece</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>an</span>t <span style='letter-spacing:-.15pt'>de</span>s fluoro<span style='letter-spacing:-.1pt'>q</span><span style='letter-spacing: -.05pt'>uinolones</span>,<span style='letter-spacing:1.85pt'> </span>y c<span style='letter-spacing:-.35pt'>o</span><span style='letter-spacing:.25pt'>m</span><span style='letter-spacing:-.05pt'>pri</span>s <span style='letter-spacing:.15pt'>l</span>a <span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.35pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.05pt'>ofloxacin</span>e<span style='letter-spacing:.05pt'> </span>; <span style='letter-spacing:-.05pt'>ces neuropathie</span>s<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.1pt'>peu</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>en</span>t<span style='letter-spacing:2.0pt'> </span>être<span style='letter-spacing:2.0pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.05pt'>déclenchemen</span>t<span style='letter-spacing:2.0pt'> </span>rapide<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.25pt'>(</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.3pt'>o</span><span style='letter-spacing:.1pt'>i</span>r<span style='letter-spacing:2.1pt'> </span><span style='letter-spacing:-.05pt'>rubriqu</span>e<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.05pt'>4.8</span>).<span style='letter-spacing:2.15pt'> </span><span style='letter-spacing:-.1pt'>L</span>a<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine<span style='letter-spacing:2.0pt'> </span>doit<span style='letter-spacing:2.05pt'> </span><span style='letter-spacing: -.1pt'>être </span>interrompue<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.05pt'>lorsqu</span>e<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:.05pt'>l</span>e<span style='letter-spacing: .65pt'> </span>patient<span style='letter-spacing:.6pt'> </span><span style='letter-spacing:-.05pt'>présent</span>e<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:-.05pt'>de</span>s<span style='letter-spacing: .8pt'> </span><span style='letter-spacing:-.05pt'>symptôme</span>s<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:.05pt'>d</span>e<span style='letter-spacing:.65pt'> </span>neuropathie,<span style='letter-spacing: .6pt'> </span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing:.3pt'>f</span><span style='letter-spacing:.05pt'>i</span>n<span style='letter-spacing:.65pt'> </span><span style='letter-spacing:-.05pt'>dévite</span>r<span style='letter-spacing:.55pt'> </span>lapparition<span style='letter-spacing: .6pt'> </span>dun état irréversible.</p>
<p class=AmmCorpsTexte><b>Opia<span style='letter-spacing:-.1pt'>cés</span></b></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>Che</span>z<span style='letter-spacing:2.2pt'> </span><span style='letter-spacing:-.05pt'>le</span>s<span style='letter-spacing:2.2pt'> </span><span style='letter-spacing:-.05pt'>patient</span>s<span style='letter-spacing:2.2pt'> </span>traités<span style='letter-spacing:2.25pt'> </span><span style='letter-spacing:-.05pt'>pa</span>r<span style='letter-spacing: 2.2pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:2.3pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine,<span style='letter-spacing: 2.0pt'> </span><span style='letter-spacing:.05pt'>l</span>e<span style='letter-spacing:2.3pt'> </span><span style='letter-spacing:-.1pt'>dosag</span>e<span style='letter-spacing:2.15pt'> </span><span style='letter-spacing:-.05pt'>de</span>s<span style='letter-spacing:2.2pt'> </span><span style='letter-spacing:-.05pt'>opiacé</span>s<span style='letter-spacing:2.2pt'> </span>dans<span style='letter-spacing:2.25pt'> </span>lurine<span style='letter-spacing:2.25pt'> </span><span style='letter-spacing:-.05pt'>peu</span>t<span style='letter-spacing:2.2pt'> </span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.35pt'>o</span><span style='letter-spacing:.15pt'>i</span>r<span style='letter-spacing:2.25pt'> </span><span style='letter-spacing:-.05pt'>des résultat</span>s <span style='letter-spacing: -.05pt'>faussemen</span>t positifs.<span style='letter-spacing:2.7pt'> </span>Il <span style='letter-spacing:-.05pt'>peu</span>t <span style='letter-spacing: .2pt'></span>être <span style='letter-spacing:.2pt'></span><span style='letter-spacing:-.05pt'>nécessair</span>e<span style='letter-spacing: .15pt'> </span><span style='letter-spacing:-.1pt'>d</span>e <span style='letter-spacing:.2pt'>confirme</span>r<span style='letter-spacing:.4pt'> </span><span style='letter-spacing:.2pt'>le</span>s <span style='letter-spacing:-.05pt'>résultat</span>s<span style='letter-spacing:.2pt'> </span>positifs<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:-.05pt'>pa</span>r une <span style='letter-spacing:.25pt'>m</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:-.05pt'>thod</span>e<span style='letter-spacing:-.05pt'> plu</span>s<span style='letter-spacing:-.05pt'> spécifique.</span></p>
<p class=AmmCorpsTexte><b><span style='letter-spacing:-.05pt'>Affection</span>s <span style='letter-spacing:-.05pt'>hépatobiliaires</span></b></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>De</span>s<span style='letter-spacing:1.3pt'> </span><span style='letter-spacing:.05pt'>ca</span>s<span style='letter-spacing:1.6pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.45pt'> </span>nécrose<span style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.05pt'>hépatiqu</span>e<span style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.1pt'>é</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.35pt'>o</span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.05pt'>uan</span>t<span style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.1pt'>e</span>n<span style='letter-spacing:1.45pt'> </span><span style='letter-spacing:-.05pt'>insuffisanc</span>e<span style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.05pt'>hépatiqu</span>e<span style='letter-spacing:1.5pt'> </span>potentiellement<span style='letter-spacing: 1.3pt'> </span>mortelle<span style='letter-spacing:1.55pt'> </span><span style='letter-spacing:-.05pt'>on</span>t<span style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.05pt'>été rapporté</span>s<span style='letter-spacing: .75pt'> </span><span style='letter-spacing:-.1pt'>a</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>e</span>c<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.65pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine,<span style='letter-spacing: .8pt'> </span><span style='letter-spacing:-.05pt'>principalemen</span>t<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>che</span>z<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing:.7pt'> </span><span style='letter-spacing:-.05pt'>patient</span>s<span style='letter-spacing:.8pt'> </span>atteints<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.75pt'> </span><span style='letter-spacing:.25pt'>pathologies</span><span style='letter-spacing: .8pt'> </span><span style='letter-spacing:-.05pt'>sou</span><span style='letter-spacing:-.25pt'>s</span>-jacentes <span style='letter-spacing: -.15pt'>sé</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>ère</span><span style='letter-spacing:-.25pt'>s</span>,<span style='letter-spacing:.95pt'> </span><span style='letter-spacing:-.05pt'>pa</span>r<span style='letter-spacing:.8pt'> </span>exemple<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.05pt'>septicémi</span>e<span style='letter-spacing: .8pt'> </span><span style='letter-spacing:-.05pt'>(voi</span>r<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>rubriqu</span>e<span style='letter-spacing:.75pt'> </span>4.8).<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.1pt'>I</span>l<span style='letter-spacing:.75pt'> </span><span style='letter-spacing:-.15pt'>con</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>ien</span>t<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>dindique</span>r<span style='letter-spacing: .8pt'> </span>aux<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.05pt'>patient</span>s<span style='letter-spacing:.75pt'> </span><span style='letter-spacing:-.05pt'>quil</span>s<span style='letter-spacing: .8pt'> </span><span style='letter-spacing:-.1pt'>doi</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>ent </span>arrêter<span style='letter-spacing:2.7pt'> </span><span style='letter-spacing:-.05pt'>leu</span>r<span style='letter-spacing:2.65pt'> </span><span style='letter-spacing:-.05pt'>traitemen</span>t<span style='letter-spacing:2.7pt'> </span>et<span style='letter-spacing:2.75pt'> </span><span style='letter-spacing:-.05pt'>contacte</span>r<span style='letter-spacing:2.45pt'> </span>leur<span style='letter-spacing:2.5pt'> </span><span style='letter-spacing: -.05pt'>médeci</span>n<span style='letter-spacing:2.7pt'> </span><span style='letter-spacing:-.2pt'>e</span>n<span style='letter-spacing:2.55pt'> </span><span style='letter-spacing:-.1pt'>ca</span>s<span style='letter-spacing:2.6pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:2.65pt'> </span><span style='letter-spacing:-.05pt'>signe</span>s<span style='letter-spacing:2.7pt'> </span>et<span style='letter-spacing:2.75pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:2.65pt'> </span><span style='letter-spacing:-.05pt'>symptôme</span>s<span style='letter-spacing:2.7pt'> </span><span style='letter-spacing:-.05pt'>daffection hépatiqu</span>e<span style='letter-spacing:.05pt'> </span>: <span style='letter-spacing:-.05pt'>anorexie</span>,<span style='letter-spacing:-.05pt'> jaunisse</span>,<span style='letter-spacing:-.05pt'> urine</span>s<span style='letter-spacing:-.05pt'> sombres</span>,<span style='letter-spacing:-.05pt'> pruri</span>t<span style='letter-spacing:-.05pt'> o</span>u<span style='letter-spacing:-.05pt'> abdome</span>n<span style='letter-spacing:-.05pt'> sensible.</span></p>
<p class=AmmCorpsTexte><b><span style='letter-spacing:-.05pt'>Exacerbatio</span>n <span style='letter-spacing:-.05pt'>dun</span>e <span style='letter-spacing: -.1pt'>m</span><span style='letter-spacing:-.05pt'>yasthéni</span>e<span style='letter-spacing:-.1pt'> grave</span></b></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>L</span>a<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.35pt'>é</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>ofloxacin</span>e<span style='letter-spacing: 1.75pt'> </span><span style='letter-spacing:-.05pt'>doi</span>t<span style='letter-spacing:1.75pt'> </span>être<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>utilisé</span>e<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing: .5pt'>v</span><span style='letter-spacing:-.05pt'>e</span>c<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>prudenc</span>e<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.05pt'>che</span>z<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>le</span>s<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.05pt'>patient</span>s<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>présentan</span>t<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.05pt'>de</span>s<span style='letter-spacing:1.7pt'> </span>antécédents<span style='letter-spacing: 1.55pt'> </span><span style='letter-spacing:.15pt'>de </span>myasthénie grave<span style='letter-spacing:-.05pt'> (voi</span>r <span style='letter-spacing:-.05pt'>rubriqu</span>e <span style='letter-spacing:-.05pt'>4.8</span>).</p>
<p class=AmmCorpsTexte><b><span style='letter-spacing:-.05pt'>Surinfection</span></b></p>
<p class=AmmCorpsTexte>Comme avec dautres antibiotiques, lutilisation de lévofloxacine, particulièrement si elle est prolongée, peut entraîner la prolifération dorganismes résistants. Lévaluation régulière de létat du patient est essentielle. Si une surinfection survient lors du traitement, des mesures appropriées devront être prises.</p>
<p class="AmmAnnexeTitre2"><a name="RcpInteractions">4.5. Interactions avec d'autres médicaments et autres formes d'interactions</a></p>
<p class=AmmAnnexeTitre3><a name="_Toc142278912"></a><a name="Rcp_4_5_Interactions_4"></a>Effets des autres médicaments sur la lévofloxacine</p>
<p class=AmmCorpsTexteGras>Sels de fer, zinc, strontium, ant<span style='letter-spacing:.05pt'>i</span>-acides contenant du magnésium ou de laluminium</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>Labsorptio</span>n<span style='letter-spacing:2.2pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:2.15pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:2.05pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine<span style='letter-spacing:2.25pt'> </span><span style='letter-spacing:-.1pt'>es</span>t<span style='letter-spacing: 2.15pt'> </span><span style='letter-spacing:-.05pt'>significativemen</span>t<span style='letter-spacing:2.2pt'> </span>réduite<span style='letter-spacing:2.0pt'> </span><span style='letter-spacing:-.05pt'>lorsq</span><span style='letter-spacing: -.1pt'>u</span>e<span style='letter-spacing:2.15pt'> </span><span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing:2.35pt'> </span><span style='letter-spacing:-.1pt'>sel</span>s<span style='letter-spacing:2.15pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:2.15pt'> </span>fer,<span style='letter-spacing:2.25pt'> </span><span style='letter-spacing:-.1pt'>d</span>u<span style='letter-spacing:2.15pt'> </span>zinc,<span style='letter-spacing:2.25pt'> </span><span style='letter-spacing:-.1pt'>du </span>strontium <span style='letter-spacing:-.1pt'>o</span>u <span style='letter-spacing:-.05pt'>de</span>s<span style='letter-spacing:2.3pt'> </span><span style='letter-spacing:-.05pt'>ant</span><span style='letter-spacing:.15pt'>i</span>-<span style='letter-spacing:-.05pt'>acide</span>s<span style='letter-spacing:2.3pt'> </span><span style='letter-spacing:-.05pt'>contenan</span>t<span style='letter-spacing:2.3pt'> </span><span style='letter-spacing:-.1pt'>d</span>u magnésium<span style='letter-spacing:2.35pt'> </span><span style='letter-spacing: -.1pt'>o</span>u <span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:2.3pt'> </span><span style='letter-spacing:.45pt'>laluminiu</span>m<span style='letter-spacing:.9pt'> </span><span style='letter-spacing:-.2pt'>s</span><span style='letter-spacing:-.05pt'>on</span>t<span style='letter-spacing:2.35pt'> </span>administrés <span style='letter-spacing:-.05pt'>concomitammen</span>t<span style='letter-spacing:1.85pt'> </span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing:.05pt'>ve</span>c<span style='letter-spacing:1.8pt'> </span><span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing:1.65pt'> </span><span style='letter-spacing:-.05pt'>comprimé</span>s<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing: 1.7pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span><span style='letter-spacing:-.05pt'>floxacin</span><span style='letter-spacing:-.1pt'>e</span>.<span style='letter-spacing:1.9pt'> </span>Il<span style='letter-spacing:1.8pt'> </span><span style='letter-spacing:-.1pt'>es</span>t<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.05pt'>recommand</span>é<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.1pt'>n</span>e<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.15pt'>pa</span>s<span style='letter-spacing:1.65pt'> </span><span style='letter-spacing:-.05pt'>prendr</span>e<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:.15pt'>de </span><span style='letter-spacing:-.05pt'>préparation</span>s<span style='letter-spacing: 1.0pt'> </span><span style='letter-spacing:-.05pt'>contenan</span>t<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.05pt'>de</span>s<span style='letter-spacing:1.0pt'> </span>cations<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.1pt'>di</span><span style='letter-spacing: .5pt'>v</span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.1pt'>ent</span>s<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.1pt'>o</span>u<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:.1pt'>t</span><span style='letter-spacing:-.05pt'>rivalent</span>s<span style='letter-spacing:1.1pt'> </span>comme<span style='letter-spacing:1.1pt'> </span><span style='letter-spacing: -.05pt'>le</span>s<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.1pt'>sel</span>s<span style='letter-spacing:1.2pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:.1pt'>fer</span>,<span style='letter-spacing:1.15pt'> </span><span style='letter-spacing:.05pt'>n</span>i<span style='letter-spacing:1.1pt'> </span><span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing:.95pt'> </span><span style='letter-spacing:-.05pt'>ant</span><span style='letter-spacing:.15pt'>i</span>-<span style='letter-spacing:-.05pt'>acides contenan</span>t<span style='letter-spacing: 1.05pt'> </span><span style='letter-spacing:-.1pt'>d</span>u<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.05pt'>magnésiu</span>m<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.1pt'>o</span>u<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.05pt'>laluminium</span>,<span style='letter-spacing:1.05pt'> </span>2 <span style='letter-spacing:-.1pt'>heure</span>s<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>an</span>t<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.1pt'>o</span>u<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.1pt'>aprè</span>s<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.05pt'>ladministratio</span>n<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.05pt'>comprimés d</span>e <span style='letter-spacing:-.05pt'>lévofloxacin</span>e <span style='letter-spacing:-.05pt'>(voi</span>r<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>rubriqu</span>e<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>4.2)</span>.<span style='letter-spacing: -.05pt'> Aucun</span>e<span style='letter-spacing:-.05pt'> interactio</span>n<span style='letter-spacing:-.05pt'> n</span>a<span style='letter-spacing:-.05pt'> ét</span>é<span style='letter-spacing:-.05pt'> détecté</span>e<span style='letter-spacing:-.05pt'> ave</span>c<span style='letter-spacing:-.05pt'> l</span>e<span style='letter-spacing:-.05pt'> carbonat</span>e<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> calcium.</span></p>
<p class=AmmCorpsTexteGras>Sucralfate</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>L</span>a<span style='letter-spacing:1.55pt'> </span>biodisponibilité <span style='letter-spacing: -.15pt'>de</span>s <span style='letter-spacing:-.05pt'>comprimé</span>s <span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.55pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.3pt'>o</span><span style='letter-spacing:-.05pt'>floxacin</span>e<span style='letter-spacing:1.6pt'> </span><span style='letter-spacing:-.1pt'>es</span>t<span style='letter-spacing: 1.55pt'> </span>significativement<span style='letter-spacing:1.6pt'> </span><span style='letter-spacing:-.05pt'>réduit</span>e <span style='letter-spacing:-.05pt'>lorsquo</span>n<span style='letter-spacing:1.6pt'> </span>les administre avec du sucralfate. Si le patient doit rece<span style='letter-spacing:.5pt'>v</span>oir du sucralfate et de la lé<span style='letter-spacing:.45pt'>v</span><span style='letter-spacing: -.05pt'>ofloxacine</span>,<span style='letter-spacing:-.05pt'> i</span>l<span style='letter-spacing:-.05pt'> convient dadministre</span>r<span style='letter-spacing:-.05pt'> l</span>e<span style='letter-spacing:-.05pt'> sucralfat</span>e<span style='letter-spacing:.1pt'> </span>2<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>heure</span>s<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>aprè</span>s<span style='letter-spacing:-.25pt'> </span>la lévofloxacine<span style='letter-spacing: -.1pt'> (</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.35pt'>o</span><span style='letter-spacing:.15pt'>i</span>r<span style='letter-spacing:-.05pt'> sectio</span>n<span style='letter-spacing:-.05pt'> 4.2).</span></p>
<p class=AmmCorpsTexteGras>Théophylline, fenbufène ou médicaments ant<span style='letter-spacing:.05pt'>i</span>-inflammatoires similaires</p>
<p class=AmmCorpsTexte>Aucune<span style='letter-spacing:1.7pt'> </span>interaction<span style='letter-spacing:1.75pt'> </span>pharmacocinétique<span style='letter-spacing: 1.75pt'> </span><span style='letter-spacing:-.1pt'>n</span>a<span style='letter-spacing:1.7pt'> </span>été<span style='letter-spacing:1.75pt'> </span>détectée<span style='letter-spacing:1.7pt'> </span>entre<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:1.8pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine<span style='letter-spacing:1.75pt'> </span>et<span style='letter-spacing:1.55pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:1.8pt'> </span>théophylline<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.1pt'>au cour</span>s<span style='letter-spacing:1.0pt'> </span>dune<span style='letter-spacing:1.05pt'> </span>étude<span style='letter-spacing:1.0pt'> </span>clinique.<span style='letter-spacing:1.1pt'> </span>Cependant,<span style='letter-spacing: 1.0pt'> </span><span style='letter-spacing:-.1pt'>u</span>n<span style='letter-spacing:1.0pt'> </span>abais<span style='letter-spacing:-.25pt'>s</span>ement<span style='letter-spacing:1.1pt'> </span>prononcé<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.1pt'>d</span>u<span style='letter-spacing: 1.25pt'> </span>seuil<span style='letter-spacing:1.05pt'> </span>épileptogène<span style='letter-spacing:1.05pt'> </span>cérébral<span style='letter-spacing:1.25pt'> </span><span style='letter-spacing:-.1pt'>p</span>eut <span style='letter-spacing: -.1pt'>sur</span><span style='letter-spacing:.5pt'>v</span>enir <span style='letter-spacing:.65pt'></span><span style='letter-spacing:-.1pt'>e</span>n <span style='letter-spacing:-.1pt'>ca</span>s<span style='letter-spacing:.6pt'> </span>dadministration concomitante<span style='letter-spacing:.65pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.6pt'> </span>quinolones et <span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing: .6pt'> </span>théophylline, <span style='letter-spacing:-.1pt'>dagent</span>s ant<span style='letter-spacing:.15pt'>i</span>- <span style='letter-spacing: .15pt'>i</span><span style='letter-spacing:-.3pt'>n</span>flammatoires ou dautres agents qui abaissent le<span style='letter-spacing:.05pt'> </span>seuil épileptogène.</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.15pt'>Le</span>s<span style='letter-spacing:1.65pt'> </span>concentrations<span style='letter-spacing: 1.75pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine<span style='letter-spacing:1.75pt'> </span>ont<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing: -.1pt'>é</span><span style='letter-spacing:.1pt'>t</span>é<span style='letter-spacing:1.7pt'> </span>environ<span style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.1pt'>1</span>3 %<span style='letter-spacing: 1.7pt'> </span>plus<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.1pt'>éle</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.15pt'>ée</span>s<span style='letter-spacing:1.65pt'> </span><span style='letter-spacing:-.1pt'>e</span>n<span style='letter-spacing:1.7pt'> </span>présence<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.7pt'> </span>fenbufène quen cas dadministration seule.</p>
<p class=AmmCorpsTexteGras>Probénécide et cimétidine</p>
<p class=AmmCorpsTexte><span style='letter-spacing: -.1pt'>L</span>e<span style='letter-spacing:2.4pt'> </span><span style='letter-spacing:-.05pt'>probénécid</span>e<span style='letter-spacing: 2.45pt'> </span>et<span style='letter-spacing:2.5pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:2.55pt'> </span>cimétidine<span style='letter-spacing:2.5pt'> </span><span style='letter-spacing:-.05pt'>on</span>t<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.1pt'>e</span>u<span style='letter-spacing:2.4pt'> </span><span style='letter-spacing:-.1pt'>u</span>n<span style='letter-spacing:2.4pt'> </span>effet<span style='letter-spacing:2.5pt'> </span>statistiquement<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.05pt'>significati</span>f<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.1pt'>su</span>r<span style='letter-spacing:2.4pt'> </span><span style='letter-spacing:-.05pt'>léliminatio</span>n<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:2.4pt'> </span><span style='letter-spacing:.05pt'>la </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine.<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.1pt'>L</span>a<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.05pt'>clairanc</span>e<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.05pt'>rénal</span>e<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.75pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine<span style='letter-spacing:.8pt'> </span>a<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing: -.05pt'>ét</span>é<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.05pt'>réduit</span>e<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.05pt'>pa</span>r<span style='letter-spacing: .8pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:1.1pt'> </span><span style='letter-spacing:-.05pt'>cimétidin</span>e<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.05pt'>(2</span>4 <span style='letter-spacing:-.05pt'>%</span>)<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.1pt'>e</span>t<span style='letter-spacing: .95pt'> </span><span style='letter-spacing:-.05pt'>pa</span>r<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:.05pt'>le </span><span style='letter-spacing:-.05pt'>probénécid</span>e<span style='letter-spacing: 1.95pt'> </span><span style='letter-spacing:-.05pt'>(3</span>4 %).<span style='letter-spacing:2.0pt'> </span><span style='letter-spacing:.4pt'>Cec</span>i<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.1pt'>es</span>t<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.1pt'>d</span>û<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.1pt'>a</span>u<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:.1pt'>fai</span>t<span style='letter-spacing:2.15pt'> </span><span style='letter-spacing:-.1pt'>qu</span>e<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.05pt'>ce</span>s<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.1pt'>d</span><span style='letter-spacing:.1pt'>eu</span>x<span style='letter-spacing:1.9pt'> </span><span style='letter-spacing:-.05pt'>médicament</span>s<span style='letter-spacing: 1.95pt'> </span><span style='letter-spacing:-.1pt'>son</span>t<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.05pt'>capable</span>s<span style='letter-spacing:2.0pt'> </span><span style='letter-spacing:.05pt'>d</span>e<span style='letter-spacing:2.05pt'> </span><span style='letter-spacing:-.05pt'>bloque</span>r<span style='letter-spacing:2.0pt'> </span><span style='letter-spacing:.15pt'>la </span><span style='letter-spacing:-.05pt'>sécrétio</span>n<span style='letter-spacing:2.2pt'> </span><span style='letter-spacing:-.05pt'>tubulair</span>e<span style='letter-spacing:2.25pt'> </span><span style='letter-spacing:-.05pt'>rénal</span>e<span style='letter-spacing:2.25pt'> </span><span style='letter-spacing:-.2pt'>d</span>e<span style='letter-spacing:2.05pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:2.05pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine.<span style='letter-spacing: 2.25pt'> </span><span style='letter-spacing:-.1pt'>Cependant</span>,<span style='letter-spacing:2.2pt'> </span><span style='letter-spacing:-.05pt'>au</span>x<span style='letter-spacing:2.2pt'> </span><span style='letter-spacing:-.15pt'>dose</span>s<span style='letter-spacing:2.1pt'> </span><span style='letter-spacing:-.05pt'>testée</span>s<span style='letter-spacing:2.2pt'> </span><span style='letter-spacing:-.05pt'>pendan</span>t<span style='letter-spacing:2.25pt'> </span>létude,<span style='letter-spacing:2.0pt'> </span>les <span style='letter-spacing:-.1pt'>di</span>fférences<span style='letter-spacing:2.0pt'> </span><span style='letter-spacing:-.05pt'>cinétique</span>s<span style='letter-spacing:1.95pt'> </span>statistiquement<span style='letter-spacing: 2.0pt'> </span><span style='letter-spacing:-.05pt'>significative</span>s<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.1pt'>n</span>e<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.05pt'>seron</span>t<span style='letter-spacing:2.0pt'> </span>probablement<span style='letter-spacing: 2.0pt'> </span><span style='letter-spacing:-.15pt'>pa</span>s<span style='letter-spacing:1.9pt'> </span><span style='letter-spacing:-.05pt'>pertinente</span>s<span style='letter-spacing:1.95pt'> </span><span style='letter-spacing:-.05pt'>su</span>r<span style='letter-spacing:2.0pt'> </span><span style='letter-spacing:.15pt'>le </span>plan clinique.</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>I</span>l <span style='letter-spacing:-.05pt'>convien</span>t<span style='letter-spacing:-.05pt'> dêtr</span>e<span style='letter-spacing:-.05pt'> pruden</span>t<span style='letter-spacing:-.05pt'> e</span>n<span style='letter-spacing:-.05pt'> ca</span>s<span style='letter-spacing:-.05pt'> dadministratio</span>n<span style='letter-spacing: -.05pt'> conjoint</span>e<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> lévofloxacin</span>e<span style='letter-spacing: -.05pt'> ave</span>c<span style='letter-spacing:-.05pt'> de</span>s<span style='letter-spacing:-.05pt'> médicament</span>s<span style='letter-spacing: -.05pt'> qui </span>affectent<span style='letter-spacing:.6pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.05pt'>sécrétio</span>n<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>rénal</span>e<span style='letter-spacing: .55pt'> </span>tubulair<span style='letter-spacing:-.1pt'>e</span>,<span style='letter-spacing:.95pt'> </span><span style='letter-spacing:-.1pt'>comm</span>e<span style='letter-spacing:.75pt'> </span><span style='letter-spacing:.05pt'>l</span>e<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.05pt'>probénécid</span>e<span style='letter-spacing:.75pt'> </span>et<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.05pt'>cimétidine</span>,<span style='letter-spacing: .8pt'> </span><span style='letter-spacing:-.1pt'>e</span>n<span style='letter-spacing:.75pt'> </span><span style='letter-spacing:-.05pt'>particulie</span>r<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>che</span>z<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>les patient</span>s<span style='letter-spacing:-.05pt'> insuffisant</span>s<span style='letter-spacing:-.05pt'> rénaux.</span></p>
<p class=AmmCorpsTexteGras>Autres informations importantes</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.15pt'>De</span>s<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:-.05pt'>étude</span>s<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.5pt'> </span>pharmacologie<span style='letter-spacing: .6pt'> </span><span style='letter-spacing:-.05pt'>cliniqu</span>e<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:.05pt'>on</span>t<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:.05pt'>montr</span>é<span style='letter-spacing:.65pt'> </span><span style='letter-spacing:-.15pt'>qu</span>e<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.65pt'> </span><span style='letter-spacing:-.05pt'>pharmacocinétiqu</span>e<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.5pt'> </span>la<span style='letter-spacing:.05pt'> </span>lévofloxacine<span style='letter-spacing:.6pt'> </span><span style='letter-spacing:-.05pt'>nest pa</span>s<span style='letter-spacing:1.0pt'> </span>affectée<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.05pt'>lorsqu</span>e<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:1.1pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.3pt'>o</span><span style='letter-spacing:.1pt'>f</span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>o</span>xacine<span style='letter-spacing:1.15pt'> </span><span style='letter-spacing:-.1pt'>es</span>t<span style='letter-spacing:1.0pt'> </span>administrée<span style='letter-spacing: 1.05pt'> </span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>e</span>c<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.05pt'>le</span>s<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.05pt'>médicament</span>s<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.15pt'>sui</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>ant</span>s<span style='letter-spacing:-.15pt'> </span>:<span style='letter-spacing:1.2pt'> </span><span style='letter-spacing:-.05pt'>carbonat</span>e<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:.05pt'>de </span><span style='letter-spacing: -.05pt'>calcium</span>,<span style='letter-spacing:-.05pt'> digoxine</span>,<span style='letter-spacing:-.05pt'> glibenclamide</span>,<span style='letter-spacing: -.05pt'> ranitidine</span></p>
<p class=AmmAnnexeTitre3>Effet de la lévofloxacine sur les autres médicaments</p>
<p class=AmmCorpsTexteGras>Ciclosporine</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>L</span>a dem<span style='letter-spacing:.15pt'>i</span><span style='letter-spacing:-.5pt'>-</span><span style='letter-spacing:.1pt'>vi</span>e <span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:.25pt'> </span><span style='letter-spacing:-.05pt'>ciclosporin</span>e a<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:-.05pt'>ét</span>é <span style='letter-spacing:-.05pt'>augmenté</span>e <span style='letter-spacing: -.1pt'>d</span>e<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:-.1pt'>3</span>3 %<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:-.05pt'>lor</span>s<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.4pt'> </span><span style='letter-spacing:-.15pt'>s</span>a c<span style='letter-spacing:-.1pt'>o</span>-adm<span style='letter-spacing:.15pt'>i</span><span style='letter-spacing:-.05pt'>nistratio</span>n<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.05pt'>e</span>c<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:.15pt'>la l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine.</p>
<p class=AmmCorpsTexteGras>Antagonistes de la vitamine K</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Un</span>e<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:-.1pt'>élé</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>atio</span>n <span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>résultat</span>s <span style='letter-spacing:-.15pt'>de</span>s <span style='letter-spacing:-.1pt'>test</span>s<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.15pt'> </span>coagulation<span style='letter-spacing: .2pt'> </span>(PT/INR)<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:-.1pt'>et</span><span style='letter-spacing:.1pt'>/</span><span style='letter-spacing:-.1pt'>o</span>u <span style='letter-spacing:-.15pt'>de</span>s <span style='letter-spacing:-.1pt'>ca</span>s dhémorragie,<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:-.1pt'>qui </span><span style='letter-spacing:-.15pt'>peu</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.1pt'>en</span>t<span style='letter-spacing:2.6pt'> </span>être<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.05pt'>graves</span>,<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.05pt'>on</span>t<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.05pt'>ét</span>é<span style='letter-spacing:2.2pt'> </span><span style='letter-spacing:-.05pt'>rapport</span><span style='letter-spacing:-.1pt'>é</span>s<span style='letter-spacing:2.25pt'> </span><span style='letter-spacing:-.05pt'>che</span>z<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.05pt'>le</span>s<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.05pt'>patient</span>s<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.05pt'>traité</span>s<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.05pt'>pa</span>r<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.1pt'>associé</span>e<span style='letter-spacing:2.4pt'> </span>à<span style='letter-spacing:2.4pt'> </span><span style='letter-spacing:.05pt'>un </span><span style='letter-spacing:-.05pt'>antagonist</span>e<span style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.45pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:1.35pt'> </span>vitamine<span style='letter-spacing:1.5pt'> </span>K<span style='letter-spacing:1.55pt'> </span><span style='letter-spacing: -.05pt'>(pa</span>r<span style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.35pt'>e</span><span style='letter-spacing:.25pt'>x</span><span style='letter-spacing:-.35pt'>e</span><span style='letter-spacing:.25pt'>m</span><span style='letter-spacing:-.35pt'>p</span><span style='letter-spacing:.15pt'>l</span>e<span style='letter-spacing:1.45pt'> </span><span style='letter-spacing:-.05pt'>warfarine)</span>.<span style='letter-spacing:1.5pt'> </span>Il<span style='letter-spacing:1.6pt'> </span><span style='letter-spacing:-.05pt'>convien</span>t<span style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.05pt'>don</span>c<span style='letter-spacing: 1.45pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.45pt'> </span><span style='letter-spacing:-.2pt'>sur</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.35pt'>e</span><span style='letter-spacing:.15pt'>i</span>ller<span style='letter-spacing:1.3pt'> </span><span style='letter-spacing:-.05pt'>le</span>s<span style='letter-spacing:1.5pt'> </span><span style='letter-spacing:-.1pt'>test</span>s<span style='letter-spacing:1.45pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.45pt'> </span><span style='letter-spacing:.15pt'>la </span><span style='letter-spacing:-.05pt'>coagulatio</span>n<span style='letter-spacing:-.05pt'> che</span>z<span style='letter-spacing:-.05pt'> le</span>s<span style='letter-spacing:-.05pt'> patient</span>s<span style='letter-spacing:-.05pt'> traité</span>s<span style='letter-spacing:-.05pt'> pa</span>r<span style='letter-spacing:-.05pt'> antagoniste</span>s<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> l</span>a<span style='letter-spacing:-.05pt'> vitamin</span>e<span style='letter-spacing:-.05pt'> </span>K<span style='letter-spacing:-.05pt'> (voi</span>r<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>rubriqu</span>e<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>4.4).</span></p>
<p class=AmmCorpsTexteGras>Médicaments connus pour allonger lintervalle QT</p>
<p class=AmmCorpsTexte>Comme avec dautres fluoroquinolones, la <span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine<span style='letter-spacing:2.45pt'> </span>doit être utilisée avec prudence chez des patients recevant des médicaments connus pour allonger lintervalle QT (par exemple, les anti-arythmiques de classe IA et III, les antidépresseurs tricycliques, les macrolides, les antipsychotiques) (voir rubrique 4.4).</p>
<p class=AmmCorpsTexteGras>Autre information pertinente</p>
<p class=AmmCorpsTexte>Dans une étude dinteraction pharmacocinétique, la lévofloxacine na pas affecté la pharmacocinétique de la théophylline (qui est un substrat du cytochrome CYP1A2), montrant ainsi que la lévofloxacine nest pas un inhibiteur du CYP1A2.</p>
<p class=AmmCorpsTexteGras>Autres formes dinteractions</p>
<p class=AmmCorpsTexte>Repas : <span style='letter-spacing:.05pt'>I</span>l<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:.05pt'>n</span>y<span style='letter-spacing:.65pt'> </span>a<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:-.05pt'>aucun</span>e<span style='letter-spacing:.5pt'> </span>interaction cliniquement<span style='letter-spacing:.6pt'> </span><span style='letter-spacing: -.05pt'>pertinent</span>e<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.15pt'>e</span>c<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:-.05pt'>le</span>s<span style='letter-spacing:.55pt'> </span>aliment<span style='letter-spacing:-.25pt'>s</span>.<span style='letter-spacing:.7pt'> </span>L<span style='letter-spacing:-.15pt'>e</span>s<span style='letter-spacing:.45pt'> </span><span style='letter-spacing:-.05pt'>comprimé</span>s<span style='letter-spacing:.55pt'> </span>de lé<span style='letter-spacing:.5pt'>v</span><span style='letter-spacing: -.05pt'>ofloxacine </span><span style='letter-spacing:-.15pt'>peu</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>en</span>t<span style='letter-spacing:-.05pt'> don</span>c<span style='letter-spacing:-.05pt'> êtr</span>e<span style='letter-spacing:-.05pt'> administré</span>s<span style='letter-spacing:-.05pt'> indépendammen</span>t<span style='letter-spacing: -.05pt'> de</span>s<span style='letter-spacing:-.05pt'> repas.</span></p>
<p class="AmmAnnexeTitre2"><a name="RcpGrossAllait">4.6. Grossesse et allaitement</a></p>
<p class=AmmAnnexeTitre2Bis><a name="_Toc142278915">Grossesse</a></p>
<p class=AmmCorpsTexte>Les études de reproduction chez lanimal nont pas révélé deffet tératogène. Cependant en labsence de données chez lhomme et du fait du risque datteinte du cartilage de soutien des organismes en croissance décrit pour les fluoroquinolones, la lévofloxacine ne doit pas être utilisée pendant la grossesse (voir rubrique 4.3). </p>
<p class=AmmAnnexeTitre2Bis>Allaitement </p>
<p class=AmmCorpsTexte>En labsence de données chez lhomme et du fait du risque datteinte du cartilage de soutien des organismes en croissance décrit pour les fluoroquinolones, la lévofloxacine ne doit pas être utilisée chez la femme qui allaite (voir rubrique 4.3).</p>
<p class="AmmAnnexeTitre2"><a name="RcpConduite">4.7. Effets sur l'aptitude à conduire des véhicules et à utiliser des machines</a></p>
<p class=AmmCorpsTexte>Certains effets indésirables (par exemple étourdissements/vertiges, somnolences, troubles visuels) peuvent affecter la capacité du patient à se concentrer et à réagir et peuvent donc représenter un risque dans des situations où ces capacités sont particulièrement importantes (par exemple conduite de véhicule, ou utilisation de machines).</p>
<p class="AmmAnnexeTitre2"><a name="RcpEffetsIndesirables">4.8. Effets indésirables</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278917"></a><a name="Rcp_4_8_EffetsIndesirables_5"></a><span style='letter-spacing:-.15pt'>Le</span>s<span style='letter-spacing:2.35pt'> </span>informations<span style='letter-spacing: 2.5pt'> </span><span style='letter-spacing:-.05pt'>présentée</span>s<span style='letter-spacing:2.45pt'> </span>c<span style='letter-spacing:.15pt'>i</span>-<span style='letter-spacing:-.1pt'>dessou</span>s<span style='letter-spacing:2.4pt'> </span>proviennent<span style='letter-spacing:2.5pt'> </span><span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing:2.35pt'> </span><span style='letter-spacing:-.05pt'>étude</span>s<span style='letter-spacing:2.45pt'> </span>cliniques<span style='letter-spacing: 2.5pt'> </span><span style='letter-spacing:-.05pt'>réalisée</span>s<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.05pt'>che</span>z<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:-.05pt'>plu</span>s<span style='letter-spacing:2.45pt'> </span><span style='letter-spacing:.05pt'>de </span>5 <span style='letter-spacing:-.1pt'>00</span>0<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>patient</span>s<span style='letter-spacing:-.05pt'> e</span>t<span style='letter-spacing:-.05pt'> de</span>s<span style='letter-spacing:-.05pt'> donnée</span>s<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> sur</span><span style='letter-spacing: .5pt'>v</span><span style='letter-spacing:-.05pt'>eillanc</span>e<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>pos</span><span style='letter-spacing:.1pt'>t</span>-<span style='letter-spacing:.25pt'>m</span><span style='letter-spacing:-.3pt'>a</span>rketin<span style='letter-spacing:-.1pt'>g</span>.</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.15pt'>Le</span>s<span style='letter-spacing:.95pt'> </span><span style='letter-spacing:-.05pt'>réaction</span>s<span style='letter-spacing:1.05pt'> </span>indésirables<span style='letter-spacing: 1.05pt'> </span>sont<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.05pt'>décrite</span>s<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.05pt'>conformémen</span>t<span style='letter-spacing:1.05pt'> </span>à<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:1.1pt'> </span><span style='letter-spacing:-.1pt'>class</span>e<span style='letter-spacing:.95pt'> </span><span style='letter-spacing:.05pt'>d</span>e<span style='letter-spacing:1.1pt'> </span><span style='letter-spacing:-.05pt'>système</span>s<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.05pt'>dorgan</span><span style='letter-spacing:.15pt'>e</span>s<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.05pt'>Me</span><span style='letter-spacing:-.1pt'>dD</span><span style='letter-spacing:.1pt'>RA </span>c<span style='letter-spacing:.15pt'>i</span>-<span style='letter-spacing:-.1pt'>dessous.</span></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>Le</span>s <span style='letter-spacing:-.05pt'>fréquence</span>s <span style='letter-spacing: -.05pt'>son</span>t <span style='letter-spacing:-.05pt'>défi</span><span style='letter-spacing:-.3pt'>n</span><span style='letter-spacing:-.05pt'>ie</span>s <span style='letter-spacing:-.05pt'>comm</span>e <span style='letter-spacing: -.05pt'>sui</span>t<span style='letter-spacing:-.05pt'> </span>: <span style='letter-spacing:-.05pt'>Trè</span>s<span style='letter-spacing:-.05pt'> fréquen</span>t<span style='letter-spacing:.2pt'> </span>(<span style='letter-spacing:-.05pt'>&#8805;1/10),</span></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>Fréquen</span>t<span style='letter-spacing:.2pt'> </span>(<span style='letter-spacing:-.05pt'>&#8805;1/100</span>,<span style='letter-spacing:-.05pt'> &lt;1/10)</span></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>Pe</span>u<span style='letter-spacing:-.05pt'> fréquen</span>t<span style='letter-spacing:.2pt'> </span>(&#8805;1/1<span style='letter-spacing:-.2pt'> </span><span style='letter-spacing:-.05pt'>000</span>,<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>&#8804;1/100), </span></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>Rar</span>e<span style='letter-spacing:.05pt'> </span>(<span style='letter-spacing:-.05pt'>&#8805;1/1</span>0 <span style='letter-spacing:-.05pt'>000</span>,<span style='letter-spacing: .05pt'> </span>&#8804;<span style='letter-spacing:-.05pt'> 1/</span>1 <span style='letter-spacing:-.1pt'>000)</span></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>Trè</span>s<span style='letter-spacing:-.05pt'> rar</span>e (<span style='letter-spacing:-.05pt'>&#8804;1/1</span>0 <span style='letter-spacing:-.1pt'>000),</span></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>Fréquenc</span>e<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>indéterminé</span>e<span style='letter-spacing:.1pt'> </span>(<span style='letter-spacing:-.05pt'>n</span>e<span style='letter-spacing:-.05pt'> peu</span>t<span style='letter-spacing:-.05pt'> êtr</span>e<span style='letter-spacing:-.05pt'> estimé</span>e<span style='letter-spacing:-.05pt'> su</span>r<span style='letter-spacing:-.05pt'> l</span>a<span style='letter-spacing:-.05pt'> bas</span>e<span style='letter-spacing:-.05pt'> de</span>s<span style='letter-spacing:-.05pt'> donnée</span>s<span style='letter-spacing:-.05pt'> disponible</span><span style='letter-spacing: -.25pt'>s</span>).</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>A</span>u<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>sei</span>n<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.05pt'>chaqu</span>e<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.05pt'>group</span>e<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.7pt'> </span>fréquenc<span style='letter-spacing:-.1pt'>e</span>,<span style='letter-spacing:1.65pt'> </span><span style='letter-spacing:-.05pt'>le</span>s<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.05pt'>effet</span>s<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>indésirable</span>s<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.1pt'>doi</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>en</span>t<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.1pt'>êtr</span>e<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.1pt'>présenté</span>s<span style='letter-spacing:1.9pt'> </span><span style='letter-spacing:-.15pt'>sui</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.1pt'>an</span>t<span style='letter-spacing:1.65pt'> </span><span style='letter-spacing:-.1pt'>un </span><span style='letter-spacing:-.05pt'>ordr</span>e<span style='letter-spacing:-.05pt'> décroissan</span>t<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> gra</span><span style='letter-spacing:.5pt'>v</span>it<span style='letter-spacing:-.1pt'>é</span>.</p>
<table class=AmmCorpsTexteTable border=0 cellspacing=0 cellpadding=0
style='margin-left:5.55pt;border-collapse:collapse'>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections cardiaques</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><i>Rares</i></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Tachycardie</p>
</td>
</tr>
<tr style='height:46.55pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:46.55pt'>
<p class=AmmCorpsTexte><i><span style='letter-spacing:-.2pt'>Fréquenc</span>e<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.2pt'>indéterminée</span></i></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:46.55pt'>
<p class=AmmCorpsTexte><span style='color:black'>arythmie ventriculaire, torsades de pointes</span> (<span style='color:black'>événements observés majoritairement chez des patients présentant des facteurs de risque dallongement de lintervalle QT</span>)<span style='color:black'>, allongement de lintervalle QT confirmé par lECG (voir rubriques 4.4 et 4.9)</span>.</p>
<p class=AmmCorpsTexte> </p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexteGras align=center style='text-align:center'>Affections hématologiques et du système lymphatique</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><i>Peu fréquents</i></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Leucopénie, éosinophilie</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><i><span style='letter-spacing:-.25pt'>Rares</span></i></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Thrombocytopénie</span>,<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.2pt'>neutropénie</span></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><i><span style='letter-spacing:-.2pt'>Fréquenc</span>e<span style='letter-spacing:-.45pt'> </span><span style='letter-spacing:-.2pt'>indéterminée</span></i></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Pancytopénie,<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>a</span>granulocytos<span style='letter-spacing: -.1pt'>e</span>,<span style='letter-spacing:.25pt'> </span>anémie hémolytique</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections<span style='letter-spacing:.1pt'> </span>du système nerveux</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><i>Fréquent</i></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Étourdissements, céphalées</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Peu fréquents</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Somnolenc<span style='letter-spacing:-.1pt'>e</span>, tremblemen<span style='letter-spacing:.1pt'>t</span>, dysgueusie</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Rares</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.15pt'>Con</span><span style='letter-spacing:.5pt'>v</span>ulsion<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.5pt'>(</span><span style='letter-spacing: .5pt'>v</span><span style='letter-spacing:-.3pt'>o</span>ir rubrique 4.2 et 4.4), paresthésie</p>
</td>
</tr>
<tr style='height:35.05pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:35.05pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Fréquenc</span>e<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.2pt'>indé</span><span style='letter-spacing:-.15pt'>t</span><span style='letter-spacing:-.2pt'>erminée</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:35.05pt'>
<p class=AmmCorpsTexte>Neuropathie périphérique<span style='letter-spacing: .05pt'> </span>sensorielle<span style='letter-spacing:-.2pt'> </span>(voir rubrique 4.4),<span style='letter-spacing:.2pt'> ou </span>sensitivomotrice (voir rubrique 4.4), parosmie incluant anosmi<span style='letter-spacing: -.1pt'>e</span>, dyskinésie, trouble extrapyramidal,<span style='letter-spacing: .1pt'> </span>agueusi<span style='letter-spacing:-.1pt'>e</span>, syncope</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections oculaires</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Rares</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Troubles visuels<span style='letter-spacing:-.1pt'> </span>tels que vision floue</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Fréquenc</span>e<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.2pt'>indéterminée</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Perte transitoire de la vision</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections de loreille et du labyrinthe</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Peu fréquents</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Vertiges</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.3pt'>R</span><span style='letter-spacing:-.2pt'>ares</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Acouphène</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Fréquence<span style='letter-spacing:.05pt'> </span>indéterminée</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Perte de laudition, <span style='letter-spacing:.1pt'>t</span>rouble<span style='letter-spacing:.05pt'> </span>de laudition</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections<span style='letter-spacing:.1pt'> </span>respiratoires,<span style='letter-spacing: .05pt'> </span>thoraciques et<span style='letter-spacing:.05pt'> </span>médiastinales</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Peu fréquents</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>Dyspnée</span></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Fréquence indéterminée</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Bronchospasm<span style='letter-spacing:-.1pt'>e</span>,<span style='letter-spacing:.25pt'> </span><span style='letter-spacing:-.1pt'>p</span>neumonie allergique</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections gastr<span style='letter-spacing:-.15pt'>o</span>-intestinales</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Fréquents</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Diarrhée,<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.25pt'>v</span>omissements,<span style='letter-spacing: .05pt'> </span>nausées</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Peu fréquents</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.1pt'>D</span>ouleurs abdominales, dyspepsie,<span style='letter-spacing:-.15pt'> </span>flatulences, constip<span style='letter-spacing:-.1pt'>a</span><span style='letter-spacing: .05pt'>tion</span></p>
</td>
</tr>
<tr style='height:35.05pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:35.05pt'>
<p class=AmmCorpsTexte>Fréquence indéterminée</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:35.05pt'>
<p class=AmmCorpsTexte>Diarrhée hémorragique pouvant dans de très rares cas<span style='letter-spacing:.1pt'> </span>indiquer<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.1pt'>une </span>entérocolite,<span style='letter-spacing:-.15pt'> </span>y compris une<span style='letter-spacing: .05pt'> </span>colite pseudomembraneuse<span style='letter-spacing:.05pt'> </span>(voir rubrique 4.4), pancréatite</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections du rein et des voies urinaires</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Peu fréquents</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Augmentation de<span style='letter-spacing:-.15pt'> </span>la créatinine sanguine</p>
</td>
</tr>
<tr style='height:23.5pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:23.5pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.3pt'>R</span><span style='letter-spacing:-.2pt'>ares</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:23.5pt'>
<p class=AmmCorpsTexte>Insuffisance rénale aiguë (par exemple due à une néphrite interstitielle)</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections de la peau et du tissu<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:.05pt'>sou</span><span style='letter-spacing:-.1pt'>s</span>-cutané</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Peu fréquents</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Eruption, pruri<span style='letter-spacing:.1pt'>t</span>, <span style='letter-spacing:-.1pt'>u</span>rticair<span style='letter-spacing: -.1pt'>e</span>,<span style='letter-spacing:.25pt'> </span><span style='letter-spacing:-.1pt'>hyperhidrose</span></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Trè</span>s<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.2pt'>rares</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>dème<span style='letter-spacing:-.3pt'> </span>de Quinck<span style='letter-spacing:-.1pt'>e</span>, réaction de photo<span style='letter-spacing:-.25pt'>s</span>ensibilité</p>
</td>
</tr>
<tr style='height:46.3pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:46.3pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Fréquenc</span>e<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.2pt'>indéterminée</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:46.3pt'>
<p class=AmmCorpsTexte>Syndrome de Lyel<span style='letter-spacing:.2pt'>l</span>, syndrome de Steven<span style='letter-spacing:-.25pt'>s</span>-Johnson, érythème <span style='letter-spacing:.25pt'>m</span><span style='letter-spacing: -.3pt'>u</span>ltiform<span style='letter-spacing:-.1pt'>e</span>, réaction de photosensibilisation (voir rubrique 4.4), vasularite leucocytoclasique, stomatite,<span style='letter-spacing:.1pt'> </span>réactions cutanéomuqueuses<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.1pt'>pou</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.1pt'>an</span>t parfois<span style='letter-spacing: -.35pt'> </span><span style='letter-spacing:-.1pt'>sur</span><span style='letter-spacing:.5pt'>v</span>enir<span style='letter-spacing:-.25pt'> </span>dès <span style='letter-spacing:.15pt'>l</span>a première<span style='letter-spacing: .1pt'> </span><span style='letter-spacing:-.1pt'>prise</span>.</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections<span style='letter-spacing:.1pt'> </span>muscul<span style='letter-spacing:-.15pt'>o</span>-squelettiques et<span style='letter-spacing:.05pt'> </span>systémiques</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Pe</span>u<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.2pt'>fréquents</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Arthralgie, myalgie</p>
</td>
</tr>
<tr style='height:46.55pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:46.55pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.25pt'>Rares</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:46.55pt'>
<p class=AmmCorpsTexte>Tendinopathies<span style='letter-spacing:-.25pt'> </span>(voir rubrique<span style='letter-spacing:.1pt'> </span>4.4) y compris<span style='letter-spacing:-.25pt'> </span>tendinite (tendon</p>
<p class=AmmCorpsTexte>dAchille),<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:.3pt'>f</span><span style='letter-spacing:-.35pt'>a</span>iblesse musculaire pou<span style='letter-spacing:.5pt'>v</span>ant être dimportance particulière chez les pa<span style='letter-spacing:.1pt'>t</span>ients présentant une myasthénie gravis (voir rubrique 4.4).</p>
</td>
</tr>
<tr style='height:23.5pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:23.5pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Fréquenc</span>e<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.2pt'>indéterminée</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:23.5pt'>
<p class=AmmCorpsTexte>Rhabdomyolyse<span style='letter-spacing:.1pt'>,</span> rupture de tendon<span style='letter-spacing:.1pt'> </span>(tendon dAchille)<span style='letter-spacing:.1pt'> </span>(voir<span style='letter-spacing:.1pt'> </span>rubrique 4.2 et<span style='letter-spacing:.1pt'> </span>4.<span style='letter-spacing: -.1pt'>4</span>), rupture musculaire, arthrite</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>T<span style='letter-spacing:-.3pt'>r</span>oubles du métabolisme et de la nutrition</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Pe</span>u<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.2pt'>fréquents</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>An<span style='letter-spacing:-.1pt'>o</span>rexie</p>
</td>
</tr>
<tr style='height:23.5pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:23.5pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.25pt'>Rares</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:23.5pt'>
<p class=AmmCorpsTexte>Hypoglycémie, en particulier chez les patients diabétiques (<span style='letter-spacing:.5pt'>v</span>oir rubrique 4.4)</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Fréquenc</span>e<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.2pt'>indéterminée</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Hyperglycémie (voir rubrique 4.4)</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Infections et infestations</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Peu fréquents</p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Infection fongiqu<span style='letter-spacing:-.1pt'>e</span>,<span style='letter-spacing:.05pt'> </span>résistance bactérienne</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections<span style='letter-spacing:-.1pt'> </span>vascula<span style='letter-spacing:.1pt'>i</span><span style='letter-spacing:-.1pt'>res</span></b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.25pt'>Rares</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Hypotension</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>T<span style='letter-spacing:-.3pt'>r</span>oubles généraux et anomalies au site dadministration</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Pe</span>u<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.2pt'>fréquents</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Asthénie</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.3pt'>R</span><span style='letter-spacing:-.2pt'>ares</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Pyrexie</p>
</td>
</tr>
<tr style='height:23.5pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:23.5pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Fréquenc</span>e<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.2pt'>indéterminée</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:23.5pt'>
<p class=AmmCorpsTexte>Douleur (y compris douleurs dans le dos, la poitrine et les extrémités)</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections<span style='letter-spacing:-.1pt'> </span>du système immunitaire</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.25pt'>Rares</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Angi<span style='letter-spacing:-.1pt'>o</span>-oedème, <span style='letter-spacing:-.1pt'>h</span>ypersensibilité (voir rubrique 4.4)</p>
</td>
</tr>
<tr style='height:35.05pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:35.05pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Fréquenc</span>e<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.2pt'>indéterminée</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:35.05pt'>
<p class=AmmCorpsTexte>Choc anaphylactique (<span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.35pt'>o</span><span style='letter-spacing:.15pt'>i</span>r<span style='letter-spacing:-.15pt'> </span>rubrique<span style='letter-spacing: .1pt'> </span>4.4).<span style='letter-spacing:-.1pt'> </span>Des<span style='letter-spacing:-.1pt'> </span>réactions anaphylactiques et anaphylactoïdes<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.15pt'>peu</span><span style='letter-spacing:.5pt'>v</span>ent<span style='letter-spacing:-.1pt'> </span>parfois<span style='letter-spacing:-.1pt'> </span>sur<span style='letter-spacing:.5pt'>v</span>enir<span style='letter-spacing:-.1pt'> </span>dès<span style='letter-spacing:-.1pt'> </span>la première prise</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections hépatobiliaires</b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.2pt'>Fréquents</span></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Aug<span style='letter-spacing:.25pt'>m</span>entation des enzymes hépatiques (A<span style='letter-spacing:-.1pt'>L</span>AT/ASAT, phosphatase </p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte> </p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>alcaline, GGT)</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><i><span style='letter-spacing:-.2pt'>Pe</span>u<span style='letter-spacing:-.4pt'> </span><span style='letter-spacing:-.2pt'>fréquents</span></i></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>Augmentatio</span>n<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> l</span>a<span style='letter-spacing:-.05pt'> bilirubin</span>e<span style='letter-spacing:-.05pt'> sanguine</span></p>
</td>
</tr>
<tr style='height:46.55pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:46.55pt'>
<p class=AmmCorpsTexte><i><span style='letter-spacing:-.2pt'>Fréquenc</span>e<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.2pt'>indéterminée</span></i></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:46.55pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>De</span>s<span style='letter-spacing:-.05pt'> ca</span>s<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> jauniss</span>e<span style='letter-spacing:-.05pt'> e</span>t<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> lésio</span>n<span style='letter-spacing:-.05pt'> hépatiqu</span>e<span style='letter-spacing: .1pt'> </span><span style='letter-spacing:-.3pt'>sé</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>èr</span>e<span style='letter-spacing:-.1pt'> </span>y<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>compri</span>s<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.1pt'>de</span>s<span style='letter-spacing: -.15pt'> </span><span style='letter-spacing:-.1pt'>cas </span><span style='letter-spacing:-.05pt'>dinsuffisanc</span>e<span style='letter-spacing: -.05pt'> hépatiqu</span>e<span style='letter-spacing:-.05pt'> aigu</span>ë<span style='letter-spacing:-.05pt'> on</span>t<span style='letter-spacing:-.05pt'> ét</span>é<span style='letter-spacing:.05pt'> </span><span style='letter-spacing: -.1pt'>rapporté</span>s<span style='letter-spacing:-.1pt'> a</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.15pt'>e</span>c<span style='letter-spacing:-.25pt'> </span><span style='letter-spacing:-.15pt'>la </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span><span style='letter-spacing:-.05pt'>floxacine</span>,<span style='letter-spacing: -.05pt'> principalemen</span>t<span style='letter-spacing:-.05pt'> che</span>z<span style='letter-spacing:-.05pt'> de</span>s<span style='letter-spacing:-.05pt'> patient</span>s<span style='letter-spacing:-.05pt'> présentan</span>t<span style='letter-spacing:-.05pt'> une </span><span style='letter-spacing:.25pt'>m</span><span style='letter-spacing:-.3pt'>a</span><span style='letter-spacing:-.05pt'>ladi</span>e<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>sou</span><span style='letter-spacing:-.25pt'>s</span>-jacente<span style='letter-spacing: .1pt'> </span><span style='letter-spacing:-.15pt'>sé</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>èr</span>e<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.1pt'>(voi</span>r<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>rubriqu</span>e<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>4.4</span><span style='letter-spacing:-.25pt'>)</span>,<span style='letter-spacing:.25pt'> </span><span style='letter-spacing:-.1pt'>h</span><span style='letter-spacing:-.05pt'>épatite</span></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=605 colspan=2 valign=top style='width:16.0cm;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'><b>Affections<span style='letter-spacing:-.3pt'> </span><span style='letter-spacing:-.05pt'>psychiatriques</span></b></p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><i><span style='letter-spacing:-.15pt'>F</span><span style='letter-spacing:-.2pt'>réquents</span></i></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte>Insomnie</p>
</td>
</tr>
<tr style='height:12.0pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><i><span style='letter-spacing:-.05pt'>Pe</span>u<span style='letter-spacing:-.05pt'> fréquents</span></i></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:12.0pt'>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>Anxiété</span>,<span style='letter-spacing:-.05pt'> éta</span>t<span style='letter-spacing:-.05pt'> confusionnel</span>,<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>nervosité</span></p>
</td>
</tr>
<tr style='height:23.5pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:23.5pt'>
<p class=AmmCorpsTexte><i><span style='letter-spacing:-.05pt'>Rare</span>s<span style='letter-spacing:.1pt'> </span>:</i></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:23.5pt'>
<p class=AmmCorpsTexte>Réacti<span style='letter-spacing:-.1pt'>o</span><span style='letter-spacing:-.15pt'>n</span>s<span style='letter-spacing:-.05pt'> psychotiqu</span><span style='letter-spacing:-.1pt'>e</span>s<span style='letter-spacing:-.05pt'> (pa</span>r<span style='letter-spacing:-.05pt'> exempl</span>e<span style='letter-spacing:-.05pt'> hallucination</span>,<span style='letter-spacing:-.05pt'> paranoïa</span>), dépression, agitation,<span style='letter-spacing:-.15pt'> rê</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>e</span>s<span style='letter-spacing:-.05pt'> anormaux</span>,<span style='letter-spacing:-.05pt'> cauchemars</span></p>
</td>
</tr>
<tr style='height:23.5pt'>
<td width=180 valign=top style='width:134.65pt;border:solid black 1.0pt;
border-top:none;padding:0cm 0cm 0cm 0cm;height:23.5pt'>
<p class=AmmCorpsTexte><i><span style='letter-spacing:-.2pt'>Fréquenc</span>e<span style='letter-spacing:-.35pt'> </span><span style='letter-spacing:-.2pt'>indéterminée</span></i></p>
</td>
<td width=425 valign=top style='width:318.95pt;border-top:none;border-left:
none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
padding:0cm 0cm 0cm 0cm;height:23.5pt'>
<p class=AmmCorpsTexte>Troubl<span style='letter-spacing:-.1pt'>e</span>s<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>psychotique</span>s<span style='letter-spacing:-.1pt'> </span><span style='letter-spacing:-.05pt'>a</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.05pt'>e</span>c<span style='letter-spacing:-.05pt'> comportemen</span>t<span style='letter-spacing: -.05pt'> d</span>e<span style='letter-spacing:-.05pt'> mis</span>e<span style='letter-spacing:-.05pt'> e</span>n<span style='letter-spacing:-.05pt'> dange</span>r<span style='letter-spacing:.05pt'> </span>y <span style='letter-spacing:-.05pt'>compri</span>s<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>idée</span>s<span style='letter-spacing:-.05pt'> o</span>u<span style='letter-spacing:-.05pt'> acte</span>s<span style='letter-spacing:-.05pt'> suicidaire</span>s<span style='letter-spacing:-.05pt'> (</span><span style='letter-spacing:.45pt'>v</span><span style='letter-spacing:-.35pt'>o</span><span style='letter-spacing:.15pt'>i</span>r<span style='letter-spacing:-.15pt'> </span><span style='letter-spacing:-.05pt'>rubriqu</span>e<span style='letter-spacing:.1pt'> </span><span style='letter-spacing:-.05pt'>4.4)</span></p>
</td>
</tr>
</table>
<p class=AmmCorpsTexteGras style='margin-top:6.0pt'>Les autr<span style='letter-spacing:-.1pt'>e</span>s<span style='letter-spacing:-.05pt'> effet</span>s<span style='letter-spacing:-.05pt'> indésirable</span>s<span style='letter-spacing:-.05pt'> associé</span>s<span style='letter-spacing:-.05pt'> </span>à<span style='letter-spacing:-.05pt'> ladministratio</span>n<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> fluoroquinolone</span>s<span style='letter-spacing:-.05pt'> incluen</span>t<span style='letter-spacing:-.2pt'> </span>:</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.05pt'>Crises d</span>e<span style='letter-spacing:-.05pt'> porphyri</span>e<span style='letter-spacing: -.05pt'> che</span>z<span style='letter-spacing:-.05pt'> le</span>s<span style='letter-spacing:-.05pt'> patient</span>s<span style='letter-spacing:-.05pt'> atteint</span>s<span style='letter-spacing:-.05pt'> d</span>e<span style='letter-spacing:-.05pt'> cett</span>e<span style='letter-spacing:-.05pt'> pathologie.</span></p>
<p class="AmmAnnexeTitre2"><a name="RcpSurdosage">4.9. Surdosage</a></p>
<p class=AmmCorpsTexte><a name="_Toc142278918"></a><a name="Rcp_4_9_Surdosage_6"></a>Selon <span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.15pt'>e</span>s <span style='letter-spacing:-.1pt'>étude</span>s<span style='letter-spacing: .15pt'> </span>toxicologiques <span style='letter-spacing:-.05pt'>menée</span>s <span style='letter-spacing:-.05pt'>che</span>z lanimal<span style='letter-spacing: .25pt'> </span><span style='letter-spacing:-.1pt'>e</span>t<span style='letter-spacing:.05pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.15pt'>es</span><span style='letter-spacing:.05pt'> </span><span style='letter-spacing:-.05pt'>étude</span>s<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:.15pt'> </span>pharmacologie<span style='letter-spacing:.2pt'> </span><span style='letter-spacing:-.05pt'>cliniq</span><span style='letter-spacing:-.1pt'>u</span>e <span style='letter-spacing:-.05pt'>réalisée</span>s<span style='letter-spacing:.55pt'> </span>à<span style='letter-spacing:.15pt'> </span><span style='letter-spacing:.05pt'>dose</span>s<span style='letter-spacing:.9pt'> </span><span style='letter-spacing:-.1pt'>supra</span>thérapeutiques,<span style='letter-spacing: .55pt'> </span>les<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.05pt'>signe</span>s<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.05pt'>le</span>s<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>plu</span>s<span style='letter-spacing:.55pt'> </span><span style='letter-spacing:-.05pt'>important</span>s<span style='letter-spacing: .55pt'> </span><span style='letter-spacing:-.05pt'>attendu</span>s<span style='letter-spacing:.8pt'> </span><span style='letter-spacing:-.05pt'>suit</span>e<span style='letter-spacing:.55pt'> </span>à<span style='letter-spacing:.5pt'> </span><span style='letter-spacing:.05pt'>u</span>n<span style='letter-spacing:.85pt'> </span><span style='letter-spacing:-.05pt'>surdosage </span>aigu<span style='letter-spacing: 1.3pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.25pt'> </span><span style='letter-spacing:.15pt'>l</span><span style='letter-spacing:-.3pt'>é</span><span style='letter-spacing:.25pt'>v</span><span style='letter-spacing:-.3pt'>o</span>floxacine<span style='letter-spacing:1.3pt'> </span><span style='letter-spacing:-.1pt'>son</span>t<span style='letter-spacing: 1.25pt'> </span><span style='letter-spacing:-.15pt'>de</span>s<span style='letter-spacing:1.4pt'> </span><span style='letter-spacing:-.05pt'>symptôme</span>s<span style='letter-spacing:1.25pt'> </span>affec<span style='letter-spacing:.05pt'>t</span><span style='letter-spacing:-.05pt'>an</span>t<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.1pt'>l</span>e<span style='letter-spacing:1.25pt'> </span>système<span style='letter-spacing:1.3pt'> </span><span style='letter-spacing:-.05pt'>nerveu</span>x<span style='letter-spacing:1.25pt'> </span><span style='letter-spacing:-.05pt'>centra</span>l<span style='letter-spacing:1.3pt'> </span><span style='letter-spacing:-.1pt'>tel</span>s<span style='letter-spacing:1.25pt'> </span><span style='letter-spacing:-.1pt'>qu</span>e<span style='letter-spacing:1.25pt'> </span>confusion, vertige<span style='letter-spacing: -.25pt'>s</span>,<span style='letter-spacing:1.2pt'> </span><span style='letter-spacing:-.05pt'>trouble</span>s<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing: 1.0pt'> </span><span style='letter-spacing:.05pt'>l</span>a<span style='letter-spacing:1.1pt'> </span><span style='letter-spacing:-.05pt'>conscience</span>,<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:-.05pt'>crise</span>s<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.05pt'>con</span><span style='letter-spacing:.5pt'>v</span><span style='letter-spacing:-.1pt'>ulsives</span>,<span style='letter-spacing:1.15pt'> </span><span style='letter-spacing:-.1pt'>a</span>llongement<span style='letter-spacing:1.1pt'> </span><span style='letter-spacing:-.1pt'>d</span>e<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.05pt'>lintervall</span>e<span style='letter-spacing:1.05pt'> </span><span style='letter-spacing:.1pt'>Q</span>T<span style='letter-spacing:1.15pt'> </span><span style='letter-spacing:-.35pt'>a</span><span style='letter-spacing:.15pt'>i</span><span style='letter-spacing:-.05pt'>ns</span>i<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.1pt'>qu</span>e<span style='letter-spacing:1.0pt'> </span><span style='letter-spacing:-.1pt'>d</span><span style='letter-spacing:.1pt'>es </span><span style='letter-spacing:-.05pt'>trouble</span>s<span style='letter-spacing:-.05pt'> digestif</span>s<span style='letter-spacing: -.05pt'> tel</span>s<span style='letter-spacing:-.05pt'> qu</span>e<span style='letter-spacing:-.05pt'> nausée</span>s<span style='letter-spacing:-.05pt'> e</span>t<span style='letter-spacing:-.05pt'> érosio</span>n<span style='letter-spacing:-.05pt'> de</span>s<span style='letter-spacing:-.05pt'> muqueuse</span><span style='letter-spacing:-.25pt'>s</span>.</p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.15pt'>Le</span>s<span style='letter-spacing:1.65pt'> </span>effets<span style='letter-spacing:1.8pt'> </span><span style='letter-spacing:-.1pt'>su</span>r<span style='letter-spacing: 1.65pt'> </span><span style='letter-spacing:.15pt'>l</span>e<span style='letter-spacing:1.45pt'> </span>S<span style='letter-spacing:-.1pt'>N</span>C<span style='letter-spacing:1.45pt'> </span>incl<span style='letter-spacing:-.1pt'>ua</span>nt<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>éta</span>t<span style='letter-spacing:1.7pt'> </span><span style='letter-spacing:-.05pt'>confusionnel</span>,<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>convulsion</span>,<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.05pt'>hallucinatio</span>n<span style='letter-spacing:1.75pt'> </span><span style='letter-spacing:-.1pt'>e</span>t<span style='letter-spacing:1.65pt'> </span><span style='letter-spacing:-.05pt'>tremblement</span>s<span style='letter-spacing:1.55pt'> </span><span style='letter-spacing:-.1pt'>on</span>t<span style='letter-spacing:1.65pt'> </span><span style='letter-spacing:-.05pt'>été rapporté</span>s<span style='letter-spacing:-.05pt'> aprè</span>s<span style='letter-spacing:-.05pt'> l</span>a<span style='letter-spacing:-.05pt'> commercialisation.</span></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.15pt;layout-grid-mode: line'>En cas de surdosage, un traitement symptomatique doit être mis en place. Un suivi électrocardiographique (ECG) doit être effectué en raison de la possibilité dallongement de lintervalle QT.</span></p>
<p class=AmmCorpsTexte><span style='letter-spacing:-.15pt'>Des anti-acides peuvent être utilisés pour protéger la muqueuse gastrique. Lhémodialyse, incluant la dialyse péritonéale et la DPCA, n'est pas efficace pour éliminer la lévofloxacine.</span></p>
<p class=AmmCorpsTexte><span style='color:black;letter-spacing:-.15pt'>Il nexiste pas dantidote spécifique.</span></p>
<p class="AmmAnnexeTitre1"><a name="RcpPropPharmacologie">5. PROPRIETES PHARMACOLOGIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpPropPharmacodynamie">5.1. Propriétés pharmacodynamiques</a></p>
<p class=AmmCorpsTexte>Classe pharmacothérapeutique: <b>Anti-infectieux à usage systémique - antibactériens à usage systémique - anti-bactériens de la classe des quinolones - fluoroquinolones</b> Code ATC: <b>J01MA12</b>.</p>
<p class=AmmCorpsTexte>La lévofloxacine est un agent antibactérien de synthèse de la classe des fluoroquinolones. Il sagit de lénantiomère S(-) de la substance médicamenteuse racémique ofloxacine.</p>
<p class=AmmCorpsTexte><b><u>Mécanisme daction</u></b></p>
<p class=AmmCorpsTexte>En tant quantibactérien de la classe des fluoroquinolones, la lévofloxacine agit sur le complexe ADN-ADN-gyrase et sur la topo-isomérase IV. </p>
<p class=AmmCorpsTexte><i><u>Relation PK/PD</u></i></p>
<p class=AmmCorpsTexte>Le degré dactivité bactéricide de la lévofloxacine dépend du ratio de laire sous la courbe (ASC) ou de la concentration sérique maximale (Cmax) et de la concentration minimale inhibitrice (CMI).</p>
<p class=AmmCorpsTexte><b><u>Mécanisme de résistance</u></b></p>
<p class=AmmCorpsTexte>Le principal mécanisme de résistance est lié à une mutation gyr-A ou par-C. On observe <i>in vitro</i> une résistance croisée entre la lévofloxacine et les autres fluoroquinolones.</p>
<p class=AmmCorpsTexte>En raison du mécanisme daction, il ny a généralement pas de résistance croisée entre la lévofloxacine et les autres classes dantibactériens.</p>
<p class=AmmCorpsTexte><b><u>Concentrations critiques</u></b></p>
<p class=AmmCorpsTexte>Les concentrations critiques sont proposées ci-dessous. Elles séparent les souches sensibles des souches de sensibilité intermédiaire, et ces dernières, des résistantes : </p>
<p class=AmmCorpsTexte><b><u>Recommandations EUCAST</u></b></p>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='border-collapse:collapse;border:none'>
<tr>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><i>Enterobacteriaceae</i> : </p>
</td>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'>S &#8804; 1 mg/L et R &gt; 2 mg/L</p>
</td>
</tr>
<tr>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><i>Pseudomonas</i> :</p>
</td>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'>S &#8804; 1 mg/L et R &gt; 2 mg/L</p>
</td>
</tr>
<tr>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><i>Acinetobacter</i> :</p>
</td>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'>S &#8804; 1 mg/L et R &gt; 2 mg/L</p>
</td>
</tr>
<tr>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><i>Staphylococcus</i> :</p>
</td>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'>S &#8804; 1 mg/L et R &gt; 2 mg/L</p>
</td>
</tr>
<tr>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><i>Streptococcus</i> A,B,C,G: </p>
</td>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'>S &#8804; 1 mg/L et R &gt; 2 mg/L</p>
</td>
</tr>
<tr>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><i>Streptococcus pneumoniae<sup>1</sup></i>:</p>
</td>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'>S &#8804; 2 mg/L et R &gt; 2 mg/L</p>
</td>
</tr>
<tr>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><i>Haemophilus influenzae, Moraxella catarrhalis</i> <sup>2</sup>:</p>
</td>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'>S &#8804; 1 mg/L et R &gt; 1 mg/L</p>
</td>
</tr>
<tr>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte>Concentrations critiques non liées à lespèce <sup>3</sup> :</p>
</td>
<td width=333 valign=top style='width:250.1pt;border:none;padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte align=center style='text-align:center'>S &#8804; 1 mg/L et R &gt; 2 mg/L</p>
</td>
</tr>
<tr>
<td width=667 colspan=2 valign=top style='width:500.2pt;border:none;
padding:0cm 5.4pt 0cm 5.4pt'>
<p class=AmmCorpsTexte><sup>1</sup> La valeur critique S/I a été passée de 1,0 à 2,0 pour éviter la division de la distribution CMI sauvage. Les valeurs critiques concernent le traitement à haute dose.</p>
<p class=AmmCorpsTexte><sup>2</sup> Les souches ayant des valeurs de CMI supérieures à la valeur critique S/I sont très rares et à ce jour aucune na été signalée. Les tests didentification et de sensibilité à lantimicrobien sur ces isolats doivent être répétés et, si le résultat est confirmé, lisolat doit être transmis à un laboratoire de référence. </p>
<p class=AmmCorpsTexte><sup>3</sup> Les concentrations critiques non liées à lespèce bactérienne ont été déterminées principalement sur la base des données pharmacocinétiques/pharmacodynamiques et sont indépendantes de la distribution des CMI despèces spécifiques. Elles ne sont à utiliser que pour les espèces nayant pas de concentration critique propre à lespèce et ne doivent pas être utilisées vis à vis despèces pour lesquelles des critères dinterprétation restent encore à déterminer.</p>
</td>
</tr>
</table>
<p class=AmmCorpsTexte style='margin-top:6.0pt'><b><u>Spectre antibactérien</u></b></p>
<p class=AmmCorpsTexte>La prévalence de la résistance acquise peut varier en fonction de la géographie et du temps pour certaines espèces. Il est donc utile de disposer dinformation sur la prévalence de la résistance locale, surtout pour le traitement dinfections sévères. Si nécessaire, il est souhaitable dobtenir un avis spécialisé principalement lorsque lintérêt du médicament dans certaines infections peut être mis en cause du fait du niveau de prévalence de la résistance locale.</p>
<p class=AmmCorpsTexte align=left style='margin-top:12.0pt;text-align:left'><b><u>ESPECES HABITUELLEMENT SENSIBLES</u></b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><b>Bactéries aérobies à gram positif</b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Staphylococcus aureus* </i>méticilline-sensible<i> </i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Staphylocoques coagulase negative méticilline-sensible, </i>incluant<i> Staphylococcus saprophyticus</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Streptococci</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Streptococcus pneumoniae*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Bacillus anthracis </i><sup>1</sup></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><b>Bactéries aérobies à gram négatif</b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Francisella tularensis</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Haemophilus influenzae*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Haemophilus para-influenzae*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Moraxella (Branhamella) catarrhalis*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Pasteurella multocida</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Proteus vulgaris</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Salmonella enterica</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Shigella</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Yersinia, </i>y compris<i> Yersinia pestis </i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><b>Bactéries anaérobies</b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Clostridium perfringens</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Fusobacterium</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Prevotella</i>$</p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Propionibacterium</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><b>Autres</b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Chlamydophila pneumoniae* </i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Chlamydophila psittaci</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Chlamydia trachomatis</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Legionella pneumophila*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Mycoplasma hominis</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Mycoplasma pneumoniae*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Ureaplasma urealyticum</i></p>
<p class=AmmCorpsTexte align=left style='margin-top:12.0pt;text-align:left'><b><u>ESPÈCES POUR LESQUELLES UNE RÉSISTANCE ACQUISE PEUT POSER PROBLÈME </u></b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><b>Bactéries aérobies à gram positif</b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Enterococcus faecalis*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Staphylococcus aureus </i>méticilline-résistant+</p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Staphylocoques coagulase négative </i>méticilline-résistant, incluant<i> Staphylococcus haemolyticus</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><b>Bactéries aérobies à gram négatif</b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Acinetobacter baumannii*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i><span lang=DE>Citrobacter freundii*</span></i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i><span lang=DE>Enterobacter aerogenes</span></i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i><span lang=DE>Enterobacter agglomerans</span></i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Enterobacter cloacae *</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Escherichia coli*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Klebsiella oxytoca</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Klebsiella pneumoniae*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Morganella morganii*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Proteus mirabilis*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Providencia rettgeri</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Providencia stuartii</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Pseudomonas aeruginosa*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Serratia marcescens*</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><b>Bactéries anaérobies</b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Peptostreptococcus</i></p>
<p class=AmmCorpsTexte align=left style='margin-top:12.0pt;text-align:left'><b><u>ESPECES NATURELLEMENT RESISTANTES</u></b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><b>Bactéries aérobies à gram positif</b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Enterococcus faecium</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><b>Bactéries aérobies à gram négatif</b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Burkholderia cepacia</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><b>Bactéries anaérobies</b></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Bacteroides</i></p>
<p class=AmmCorpsTexte align=left style='text-align:left'><i>Clostridium difficile</i></p>
<p class=AmmCorpsTexte>* : Lefficacité clinique a été démontrée pour des isolats sensibles dans les indications cliniques approuvées.</p>
<p class=AmmCorpsTexte>$ : Sensibilité intermédiaire naturelle</p>
<p class=AmmCorpsTexte>+ : Plus de 50 % de résistance</p>
<p class=AmmCorpsTexte><sup>1</sup>: <i>Bacillus anthracis</i> : la lévofloxacine sest révélée efficace pour une prophylaxie post-exposition dans un modèle expérimental murin de maladie du charbon par inhalation.</p>
<p class=AmmCorpsTexte><b>Autres informations</b></p>
<p class=AmmCorpsTexte>Les infections nosocomiales dues à <i>P. aeruginosa </i>peuvent nécessiter un traitement combiné.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPropPharmacocinetique">5.2. Propriétés pharmacocinétiques</a></p>
<p class=AmmCorpsTexte><b><u>Absorption</u></b></p>
<p class=AmmCorpsTexte>La lévofloxacine, administrée par voie orale, est absorbée rapidement et presque totalement, avec des concentrations plasmatiques maximales obtenues en 1 heure. La biodisponibilité absolue est d'environ 100 %.</p>
<p class=AmmCorpsTexte>Les aliments ont peu d'effet sur l'absorption de la lévofloxacine.</p>
<p class=AmmCorpsTexte><b><u>Distribution</u></b></p>
<p class=AmmCorpsTexte>Environ 30-40 % de la lévofloxacine est liée aux protéines sériques. L'administration répétée de 500 mg une fois par jour de lévofloxacine a entraîné une accumulation négligeable. On observe une accumulation modeste mais prévisible de lévofloxacine après des doses de 500 mg deux fois par jour. L'état d'équilibre est atteint en 3 jours.</p>
<p class=AmmCorpsTexte><b><u>Pénétration dans les tissus et les liquides de l'organisme</u></b></p>
<p class=AmmCorpsTexte><i>Pénétration dans la muqueuse bronchique, le film épithélial alvéolaire</i></p>
<p class=AmmCorpsTexte>Les concentrations maximales de lévofloxacine dans la muqueuse bronchique et le film épithélial alvéolaire après administration de 500 mg par voie orale ont été de 8,3 µg/g et 10,8 µg/ml, respectivement. Ces concentrations ont été atteintes environ une heure après administration.</p>
<p class=AmmCorpsTexte><i>Pénétration dans le tissu pulmonaire</i></p>
<p class=AmmCorpsTexte>Les concentrations maximales de lévofloxacine dans le tissu pulmonaire après administration de 500 mg <i>per os</i> ont été d'environ 11,3 µg/g et ont été atteintes entre 4 et 6 heures après administration. Les concentrations dans les poumons ont été constamment supérieures aux concentrations plasmatiques.</p>
<p class=AmmCorpsTexte><i>Pénétration dans le liquide interstitiel</i></p>
<p class=AmmCorpsTexte>Des concentrations maximales de lévofloxacine d'environ 4,0 et 6,7 µg/ml dans le liquide interstitiel ont été atteintes 2-4 heures après l'administration après trois jours de traitement par 500 mg une ou deux fois par jour, respectivement.</p>
<p class=AmmCorpsTexte><i>Pénétration dans le liquide céphalo-rachidien</i></p>
<p class=AmmCorpsTexte>La lévofloxacine pénètre faiblement dans le liquide céphalo-rachidien.</p>
<p class=AmmCorpsTexte><i>Pénétration dans le tissu prostatique</i></p>
<p class=AmmCorpsTexte>Après administration par voie orale de 500 mg de lévofloxacine une fois par jour pendant trois jours, les concentrations moyennes dans le tissu prostatique ont été de 8,7 µg/g, 8,2 µg/g et 2,0 µg/g respectivement après 2 heures, 6 heures et 24 heures; le ratio moyen concentration prostatique/concentration plasmatique était de 1,84.</p>
<p class=AmmCorpsTexte><i>Concentration urinaire</i></p>
<p class=AmmCorpsTexte>Les concentrations urinaires moyennes 8-12 heures après administration d'une seule dose orale de 150 mg, 300 mg ou 500 mg de lévofloxacine ont été de 44 mg/l, 91 mg/l et 200 mg/l, respectivement.</p>
<p class=AmmCorpsTexte><b><u>Biotransformation</u></b></p>
<p class=AmmCorpsTexte>La lévofloxacine est très peu métabolisée, ses principaux métabolites étant la déméthyl-lévofloxacine et la lévofloxacine N-oxyde. Ces métabolites représentent moins de 5 % de la dose excrétée dans l'urine. La lévofloxacine est stéréochimiquement stable et ne subit pas d'inversion chirale.</p>
<p class=AmmCorpsTexte><b><u>Elimination</u></b></p>
<p class=AmmCorpsTexte>Après administration orale et intraveineuse, la lévofloxacine est éliminée relativement lentement du plasma (t½: 6-8 heures). L'excrétion a lieu principalement par voie rénale (plus de 85 % de la dose administrée). Il n'y a pas de différence majeure dans la pharmacocinétique de la lévofloxacine administrée par voie intraveineuse ou orale, ce qui montre que ces deux voies sont interchangeables.</p>
<p class=AmmCorpsTexte><b><u>Linéarité</u></b></p>
<p class=AmmCorpsTexte>La lévofloxacine suit une pharmacocinétique linéaire sur une plage de 50 à 600 mg.</p>
<p class=AmmCorpsTexte><b><u>Insuffisant rénal</u></b></p>
<p class=AmmCorpsTexte>La pharmacocinétique de la lévofloxacine est affectée par l'insuffisance rénale. Lorsque la fonction rénale est atteinte, l'élimination et la clairance rénales diminuent et la demi-vie d'élimination augmente, comme le montre le tableau ci-dessous:</p>
<table class=AmmCorpsTexteTable border=1 cellspacing=0 cellpadding=0
style='margin-left:3.5pt;border-collapse:collapse;border:none'>
<thead>
<tr>
<td width=169 valign=top style='width:126.5pt;border:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Cl<sub>cr</sub> [ml/min]</p>
</td>
<td width=169 valign=top style='width:126.5pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>&lt; 20</p>
</td>
<td width=169 valign=top style='width:126.5pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>20 - 40</p>
</td>
<td width=169 valign=top style='width:126.5pt;border:solid windowtext 1.0pt;
border-left:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>50 - 80</p>
</td>
</tr>
<tr>
<td width=169 valign=top style='width:126.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>Cl<sub>R</sub> [ml/min]</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>13</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>26</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>57</p>
</td>
</tr>
<tr>
<td width=169 valign=top style='width:126.5pt;border:solid windowtext 1.0pt;
border-top:none;padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>t½ [h]</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>35</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>27</p>
</td>
<td width=169 valign=top style='width:126.5pt;border-top:none;border-left:
none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
padding:0cm 3.5pt 0cm 3.5pt'>
<p class=AmmCorpsTexte align=left style='margin-bottom:0cm;margin-bottom: .0001pt;text-align:left'>9</p>
</td>
</tr>
</thead>
</table>
<p class=AmmCorpsTexte><b><u>Sujet âgé</u></b></p>
<p class=AmmCorpsTexte>Il n'y a pas de différence significative entre la cinétique de la lévofloxacine chez le sujet âgé et chez le sujet jeune, sauf celle liée aux différences de clairance de la créatinine.</p>
<p class=AmmCorpsTexte><b><u>Différences en fonction du sexe</u></b></p>
<p class=AmmCorpsTexte>Les analyses réalisées séparément pour des hommes et des femmes ont montré des différences faibles à marginales de pharmacocinétique de la lévofloxacine en fonction du sexe. Aucun élément n'indique que ces différences liées au sexe ont une pertinence clinique.</p>
<p class="AmmAnnexeTitre2"><a name="RcpSecuritePreclinique">5.3. Données de sécurité préclinique</a></p>
<p class=AmmCorpsTexte><a name="Rcp_5_3_SecuritePreclinique_7"></a><b>Toxicité aiguë</b></p>
<p class=AmmCorpsTexte>Les valeurs médianes de DL<sub>50</sub> obtenues chez la souris et le rat après administration orale de lévofloxacine ont été comprises dans la plage de 1 500 - 2 000 mg/kg. L'administration de 500 mg/kg au singe par voie orale a produit peu d'effet hormis des vomissements.</p>
<p class=AmmCorpsTexte><b>Toxicité de doses répétées</b></p>
<p class=AmmCorpsTexte>Des études sur un et six mois par gavage ont été réalisées chez le rat et le singe. Les doses ont été de 50, 200, 800 mg/kg/jour et de 20, 80, 320 mg/kg/jour pendant 1 et 6 mois chez le rat et de 10, 30, 100 mg/kg/jour et de 10, 25, 62,5 mg/kg/jour pendant 1 et 6 mois chez le singe.</p>
<p class=AmmCorpsTexte>Les signes de réaction au traitement ont été mineurs chez le rat, avec des effets légers principalement à 200 mg/kg/jour et au-delà: diminution de la prise alimentaire et légère altération des paramètres hématologiques et biochimiques.</p>
<p class=AmmCorpsTexte>Les « doses sans effets toxiques », dans ces études, ont été de 200 et 20 mg/kg/jour après 1 et 6mois respectivement.</p>
<p class=AmmCorpsTexte>La toxicité après administration orale chez le singe a été minime: perte de poids à 100 mg/kg/jour, avec salivation, diarrhées et diminution du pH urinaire chez certains animaux à cette dose. Aucune toxicité n'a été observée au cours de l'étude de 6 mois. Il en a été conclu que les doses sans effets toxiques étaient de 30 et 62,5 mg/kg/jour après 1 et 6 mois respectivement.</p>
<p class=AmmCorpsTexte>Il en a été conclu que les doses sans effets toxiques dans les études de six mois étaient de 20 et 62,5 mg/kg/jour chez le rat et le singe respectivement.</p>
<p class=AmmCorpsTexte><b>Effets sur la reproduction</b></p>
<p class=AmmCorpsTexte>La lévofloxacine n'a pas altéré la fertilité ni les performances de reproduction du rat à des doses orales atteignant 360 mg/kg/jour ni à des doses intraveineuses atteignant 100 mg/kg/jour.</p>
<p class=AmmCorpsTexte>La lévofloxacine n'a pas été tératogène chez le rat à des doses orales atteignant 810 mg/kg/jour, ni à des doses intraveineuses atteignant 160 mg/kg/jour. Aucun pouvoir tératogène n'a été observé lorsque les lapins ont reçu par voie orale une dose atteignant 50 mg/kg/jour ou par voie intraveineuse une dose atteignant 25 mg/kg/jour.</p>
<p class=AmmCorpsTexte>La lévofloxacine n'a pas eu d'effet sur la fertilité et son seul effet sur les ftus a été un retard de maturation résultant de la toxicité maternelle.</p>
<p class=AmmCorpsTexte><b>Génotoxicité</b></p>
<p class=AmmCorpsTexte>La lévofloxacine n'a pas produit de mutation génétique dans les cellules bactériennes ni mammifères mais a produit des aberrations chromosomiques dans des cellules pulmonaires de hamster chinois (CHL) <i>in vitro</i> à des concentrations supérieures ou égales à 100 µg/ml, en l'absence d'activation métabolique. Les tests <i>in vivo</i> (micronucleus, échange de chromatides surs, synthèse non programmée d'ADN, dominant létal) n'ont révélé aucun potentiel génotoxique.</p>
<p class=AmmCorpsTexte><b>Potentiel phototoxique</b></p>
<p class=AmmCorpsTexte>Des études réalisées sur la souris après administration orale et intraveineuse ont montré que la lévofloxacine n'a une activité phototoxique qu'à des doses très élevées. Un test de photomutagénicité n'a révélé aucun potentiel génotoxique de la lévofloxacine, qui a par ailleurs réduit le développement tumoral dans un test de photocarcinogénicité.</p>
<p class=AmmCorpsTexte><b>Potentiel carcinogène</b></p>
<p class=AmmCorpsTexte>Aucune indication de potentiel carcinogène n'a été détectée au cours d'une étude de deux ans réalisée chez le rat recevant 0, 10, 30 et 100 mg/kg/jour.</p>
<p class=AmmCorpsTexte><b>Toxicité articulaire</b></p>
<p class=AmmCorpsTexte>Comme les autres fluoroquinolones, la lévofloxacine a eu des effets sur le cartilage (formation de vésicules et de cavités) chez le rat et le chien. Ces résultats ont été plus marqués chez les animaux jeunes.</p>
<p class="AmmAnnexeTitre1"><a name="RcpDonneesPharmaceutiques">6. DONNEES PHARMACEUTIQUES</a></p>
<p class="AmmAnnexeTitre2"><a name="RcpListeExcipients">6.1. Liste des excipients</a></p>
<p class=AmmCorpsTexte><a name="Rcp_6_1_ListeExcipients_8"></a><u>Noyau du comprimé</u>:</p>
<p class=AmmCorpsTexte>Silice colloïdale anhydre</p>
<p class=AmmCorpsTexte>Hydroxypropylcellulose</p>
<p class=AmmCorpsTexte>Carboxyméthylamidon sodique (type A)</p>
<p class=AmmCorpsTexte>Talc</p>
<p class=AmmCorpsTexte>Croscarmellose sodique</p>
<p class=AmmCorpsTexte>Stéarate de magnésium</p>
<p class=AmmCorpsTexte><u>Pelliculage</u>:</p>
<p class=AmmCorpsTexte>Hypromellose</p>
<p class=AmmCorpsTexte>Dioxyde de titane (E171)</p>
<p class=AmmCorpsTexte>Macrogol 400</p>
<p class=AmmCorpsTexte>Polysorbate 80</p>
<p class=AmmCorpsTexte>Oxyde de fer noir (E172)</p>
<p class=AmmCorpsTexte>Oxyde de fer jaune (E172)</p>
<p class=AmmCorpsTexte>Oxyde de fer rouge (E172)</p>
<p class="AmmAnnexeTitre2"><a name="RcpIncompatibilites">6.2. Incompatibilités</a></p>
<p class=AmmCorpsTexte>Sans objet.</p>
<p class="AmmAnnexeTitre2"><a name="RcpDureeConservation">6.3. Durée de conservation</a></p>
<p class=AmmCorpsTexte>2 ans.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPrecConservation">6.4. Précautions particulières de conservation</a></p>
<p class=AmmCorpsTexte>A conserver dans l'emballage extérieur d'origine à l'abri de la lumière.</p>
<p class="AmmAnnexeTitre2"><a name="RcpEmballage">6.5. Nature et contenu de l'emballage extérieur</a></p>
<p class=AmmCorpsTexte>1, 2, 5, 7, 10, 30, 50, 50 (5x10), 200 (20x10), 500 (50x10) comprimés pelliculés sécables sous plaquettes thermoformées PVC/PVDC/aluminium.</p>
<p class=AmmCorpsTexte>Toutes les présentations peuvent ne pas être commercialisées.</p>
<p class="AmmAnnexeTitre2"><a name="RcpPrecEmpl">6.6. Précautions particulières délimination et de manipulation</a></p>
<p class=AmmCorpsTexte>Pas d'exigences particulières.</p>
<p class=AmmCorpsTexte>Tout produit non utilisé ou déchet doit être éliminé conformément à la réglementation en vigueur.</p>
<p class="AmmAnnexeTitre1"><a name="RcpTitulaireAmm">7. TITULAIRE DE LAUTORISATION DE MISE SUR LE MARCHE</a></p>
<p class=AmmTitulaireNom>TEVA SANTE</p>
<p class=AmmTitulaireAdresse>110, ESPLANADE DU GENERAL DE GAULLE</p>
<p class=AmmTitulaireAdresse>92931 PARIS-LA-DEFENSE CEDEX</p>
<p class="AmmAnnexeTitre1"><a name="RcpPresentation">8. NUMERO(S) DAUTORISATION DE MISE SUR LE MARCHE</a></p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>391 099-0 ou 34009 391 099 0 9: 1 comprimé pelliculé sécable sous plaquettes thermoformées PVC/PVDC/Aluminium.</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>391 100-9 ou 34009 391 100 9 7: 2 comprimés pelliculés sécables sous plaquettes thermoformées PVC/PVDC/Aluminium.</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>391 101-5 ou 34009 391 101 5 8: 5 comprimés pelliculés sécables sous plaquettes thermoformées PVC/PVDC/Aluminium.</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>391 102-1 ou 34009 391 102 1 9: 7 comprimés pelliculés sécables sous plaquettes thermoformées PVC/PVDC/Aluminium.</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>391 103-8 ou 34009 391 103 8 7: 10 comprimés pelliculés sécables sous plaquettes thermoformées PVC/PVDC/Aluminium.</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>391 104-4 ou 34009 391 104 4 8: 30 comprimés pelliculés sécables sous plaquettes thermoformées PVC/PVDC/Aluminium.</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>391 105-0 ou 34009 391 105 0 9: 50 comprimés pelliculés sécables sous plaquettes thermoformées PVC/PVDC/Aluminium.</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>574 294-7 ou 34009 574 294 7 8: 50 (5x10) comprimés pelliculés sécables sous plaquettes thermoformées PVC/PVDC/Aluminium.</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>574 295-3 ou 34009 574 295 3 9: 200 (20x10) comprimés pelliculés sécables sous plaquettes thermoformées PVC/PVDC/Aluminium.</p>
<p class=AmmListePuces1><span style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>         </span></span>574 297-6 ou 34009 574 297 6 8: 500 (50x10) comprimés pelliculés sécables sous plaquettes thermoformées PVC/PVDC/Aluminium.</p>
<p class="AmmAnnexeTitre1"><a name="RcpPremiereAutorisation">9. DATE DE PREMIERE AUTORISATION/DE RENOUVELLEMENT DE LAUTORISATION</a></p>
<p class=AmmCorpsTexte>[à compléter par le titulaire]</p>
<p class="AmmAnnexeTitre1"><a name="RcpDateRevision">10. DATE DE MISE A JOUR DU TEXTE</a></p>
<p class=AmmCorpsTexte>[à compléter par le titulaire]</p>
<p class="AmmAnnexeTitre1"><a name="RcpDosimetrie">11. DOSIMETRIE</a></p>
<p class=AmmCorpsTexte>Sans objet.</p>
<p class="AmmAnnexeTitre1"><a name="RcpInstPrepRadioph">12. INSTRUCTIONS POUR LA PREPARATION DES RADIOPHARMACEUTIQUES</a></p>
<p class=AmmCorpsTexte>Sans objet.</p>
<div style='border:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0cm 0cm 0cm'>
<p class="AmmAnnexeTitre"><a name="RcpCondPrescription">CONDITIONS DE PRESCRIPTION ET DE DELIVRANCE</a></p>
</div>
<p class=AmmCorpsTexte>Liste I.</p>
<p class=AmmAnnexeTitre><a name="_Toc142278936"></a></p>
<b><span style='font-size:12.0pt;font-family:Arial;color:#0B3D92;text-transform:
uppercase'><br clear=all>
</span></b>
</BODY>
</HTML>
